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9ABSTRACT
Leukocyte motility is known to be dependent on both b2-integrins and matrix metalloproteinases
MMP-2/-9 or gelatinases, capable of mediating leukocyte adhesion and the proteolysis needed for invasion,
respectively. We have used phage display technology to identify peptide sequences interacting with the aM
integrin I domain, an about 200 amino acid residue sequence known to be responsible for ligand binding in
b2 integrins. One of the peptides contained a sequence very similar to the conserved DELW(S/T)LG
sequence found in MMP-2 and –9. In several binding, migration and mutation analysis studies, we showed
that the integrin recognition sequence mapped to the MMP catalytic domain, specifically bound to the aM I
domain, and it inhibited migration of leukocytes in vitro. Subcellular fractionation experiments revealed that
the proMMP-9/aMb2 complex was formed intracellularly and could be translocated to the cell surface upon
cell activation. This interaction was efficiently blocked by a peptide sequence derived from the catalytic
domain of MMP-9. Also, a novel small-molecule ligand to the aM I domain, identified by screening a
combinatorial library, inhibited DDGW-phage binding to the I domain and reduced leukocyte infiltration to
an inflammatory site in vivo. The concept that MMPs associate with integrins, as well as its importance in
some physiological and pathological conditions has been advanced previously but has not been examined on
leukocytes.
Gelatinases not only play an important role in cell migration, tissue remodelling and angiogenesis
during development, but are also involved in the progression and invasiveness of many cancers, including
leukemias. We showed that MMP-9 association with b2 integrins seems to play an important role in leukemia
growth and dissemination in vivo, as inhibition of complex formation significantly improved the survival of
mice that developed leukemia. These findings suggest that the integrin/MMP-9 complex may serve as a
functional target for intervention in human acute leukemias.
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REVIEW OF THE LITERATURE
LEUKOCYTE ADHESION AND MIGRATION
THE LEUKOCYTE MIGRATION CASCADE
Leukocytes or white blood cells (WBC) are bone marrow-derived cells and principal components of
the immune system. They circulate in the bloodstream as passive, non-polarized cells and function by
destroying “nonself” substances, including invading microbes, bacteria, and viruses. Over the past two
decades, much progress has been made towards elucidating the molecular basis of leukocyte migration from
the bloodstream to the tissues (reviewed in Butcher, 1991; Springer, 1995; Carlos and Harlan; 1994; von
Andrian and Mackay, 2000; McIntyre et al., 2003). Recruitment of neutrophils from the blood to the
inflamed tissues requires a sequence of adhesion and activation events which are mediated by several
adhesion molecules, including mainly selectins (that bind to their carbohydrate-based ligands) and integrins
(that interact with cell adhesion molecules or CAMs) (Vestweber and Blanks, 1999; von Andrian and
Mackay, 2000) (Figure 1).
At least four steps of adhesion and activation events are required for a succesful extravasation of
leukocytes from the vascular lumen to the tissues: (I) “Thethering and rolling” is the initial and essential
event in leukocyte recruitment. It describes a process of weak adhesive interactions between the surfaces of
the neutrophil and the endothelial cell, largely mediated by three members of the selectin family and their
highly glycosylated ligands. Weak adhesive interactions between selectins and their ligands tether
neutrophils to the vascular endothelium, and under shear flow, causes them to crawl along it. Such
interactions can also initiate signals which promote the opening of cell-cell junctions, allowing leukocytes to
pass between tissue (Johnson-Leger et al., 2000) or within (transcytosis; Middleton et al., 1997) endothelial
cells in order to reach the underlying tissue.
Selectins are a family of cell surface adhesion glycoproteins, which share a conserved sequence and
named according to their main expression sites. L-selectin (LECAM-1, CD62L) is expressed exclusively on
leukocytes, whereas E-selectin (ELAM-1, CD62E) and P-selectin (GMP-140, CD62L) are expressed on
endothelial cells. P selectin is also found in platelets.
(II) “Slow rolling and activation” is associated with increased integrin avidity, which can be elicited
by soluble and/or membrane bound chemokines or other chemotactic compounds, such as bacterial peptides,
the platelet activating factor (PAF) or leukotriene B4.
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Functions Leukocytes (receptors) Endothelium (ligands)
I
L-selectin
PSGL-1,CD24, sLeX
ESL-1, CLA, L-selectin, SSEA-1
CD34, sLeX, PSGL-1,
GlyCAM, MAdCAM-1, CD14
P-selectin
E-selectin
II
aL/M/X/Db2
a4b1
a4b7
Chemokine receptors
ICAMs, VCAM-1, iCb3, FG
VCAM-1, ECM
VCAM-1, MAdCAM-1, FN
Chemokines
III
PECAM-1
aLb2
aMb2
a4b1
PECAM-1
JAM-A
JAM-C
CD99
PECAM-1
ICAMs, JAM-A
ICAMs, JAM-C (on platelets)
VCAM-1, ECM, CD44, JAM-B
PECAM-1, aVb3
JAM-A ?
JAM-C
CD99
Figure 1. Adhesion molecules involved in different steps of the leukocyte adhesion /migration cascade. CD, cluster
of differentiation; CAM, cell adhesion molecule; ICAM, intercellular CAM; CLA, cutaneous lymphocyte antigen;
ECM, extracellular matrix; ESL, E-selectin ligand; MAdCAM, mucosal addressin CAM; PSGL, P-selectin glycoprotein
ligand; SSEA, sialyl stage-specific embryonic antigen; VCAM, vascular endothelial CAM; sLeX, sialyl Lewis X; FG,
fibrinogen; JAM, junctional adhesion molecule; PECAM-1, platelet-endothelial-cell adhesion molecule-1.
Chemokines are a large family of extracellular signaling molecules, capable of signaling through G-
protein-coupled receptors and being key regulators of the immune system (reviewed in Mackay, 2001). They
are also known to function as modulators of adhesion events mediated by integrins and selectins, and to
regulate the order and timing of integrin adhesions. Treatment of cells with several chemokines promotes b2-
integrin-mediated adhesions to ICAMs by increasing b2-integrin clustering and affinity in leukocytes (Goda
et al., 2000). However, several chemokines induce adhesion through activation of a4b1, another major
leukocyte integrin, but this activation is often followed by inactivation and leukocyte detachment (Weber et
12
al., 1996; Grabovsky et al., 2000), suggesting that chemokines may shift leukocytes from a4b1- to b2-
mediated adhesions. Moreover, in order for these adhesive events to occur, it has been suggested that
chemokines should be first immobilized by various proteoglycans on the luminal endothelial surface and
presented in a bound form to neutrophils (Rot, 1992; Tanaka et al., 1993).
(III) “Firm adhesion” and “Transmigration” are both mediated mostly by integrins and their ligands.
Firm adhesion of neutrophils to activated endothelium is a step required for further transendothelial
migration and disruption of the tight barriers formed by endothelial junctional proteins. It appears that aMb2-
integrin is one of the key molecules responsible for firm adhesion of neutrophils to the vascular endothelium
in vivo (Bunting et al., 2002), as treatment of animals with anti-b2 antibodies resulted in inhibition of cell
adhesion after an inflammatory stimulus (Arfors et al., 1987).
To date, despite the intense studies performed by several investigators using techniques such as
intravital, fluorescence, and electron microscopy, it still remains unclear which exact pathway neutrophils
use to migrate out of blood vessels. These techniques allowed the elucidation of two migration pathways: (1)
neutrophil migration at intercellular junctions (paracellular migration) (Marchesi and Florey, 1960; Burns et
al., 2000; Shaw et al., 2001) and (2) neutrophil migration through an endothelial cell body (transcellular
migration) (Feng et al., 1998). For a successful paracellular migration, neutrophils need to cross the
endothelial cell-cell junctions formed by a large number of proteins, including the vascular endothelial (VE)-
cadherin, members of the junction adhesion molecule (JAM) family, claudins, CD99, occludin and PECAM-
1 (Figure 1). Antibodies against PECAM-1 dramatically decreased transendothelial migration, both in vitro
(Muller et al., 1993; Christofidou-Solomidou et al., 1997) and in vivo (Vaporciyan et al., 1993; Mamdouh et
al., 2003).  In addition, chemoattractant gradients play essential roles in providing routes to leukocytes for
polarized migration through the endothelium, and through the ECM into the tissue (Foxman et al., 1997).
NEUTROPHIL FUNCTION AND ADHESION DURING INFLAMMATION
Neutrophils, also known as polymorphonuclear leukocytes (PMNs) originate from stem cells in the
bone marrow. They represent 60-70% of the total circulating leukocytes and are the first cells to be recruited
to the sites of infection or injury within minutes to hours after maturation, forming a primary defense against
infectious agents or “foreign” substances that invade our body’s physical barriers. The initiation of an
inflammatory response involves three major steps: (1) increased blood flow by dilation of capillaries; (2)
escape of plasma proteins from the bloodstream; (3) and extravasation of neutrophils through the
endothelium and accumulation at the site of injury. Elimination of invading microorganisms is accomplished
by phagocytosis, generation of reactive oxygen metabolites, as well as through release of proteolytic
enzymes and microbicidal substances, all stored in intracellular granules of mature PMNs (Bainton, 1999).
The main functions of neutrophils describe adhesion, extravasation, chemotaxis, phagocytosis, and
production of oxidative agents. Like all leukocytes, these functions can be triggered by appropriate stimuli
and the synergistic action of different adhesion molecules that are present on the surface of both neutrophils
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and activated endothelial cells (reviewed in Zimmerman et al., 1992; Carlos and Harlan, 1994). Interactions
of neutrophils with the activated endothelium have been extensively studied either under static conditions or
under physiological conditions (flow shear forces). A new technique was developed to study neutrophil
arrest in inflamed venules in vivo, called leukocyte tracking (reviewed in Ley, 2002). Neutrophil tethering
and capture has been shown to be mediated by P-selectin-binding to its ligand PSGL-1; neutrophil activation
by chemokines, such as IL-8; and firm adhesion by ICAM-1-binding to aLb2 and aMb2 integrins (Divietro et
al., 2001). Chemokines, capable of triggering rapid arrest of T cells, B cells, and monocytes on endothelial
cells under physiological conditions include SLC/CCL21, RANTES, and SLC/CCL21 or SDF-1/CXCL12,
respectively. Unlike other leukocytes, arrest chemokines for neutrophils have been much difficult to define,
even though the neutrophil adhesion cascade has been studied longer and by more groups. In certain in vitro
systems, rapid neutrophil adhesion can be triggered by a single chemoattractant, such as IL-8, the platelet
activating factor (PAF), complement C5a, formyl peptides, and leukotriene LTB4. However, the presence of
a single chemoattractant has little effect on P-selectin-dependent neutrophil rolling and chemoattractant-
dependent activation in most inflammatory models in vivo. In contrary to naive T cells, neutrophils need
multiple inputs for full activation rather than a single arrest chemokine, mediated by additive or even
synergistic signals through G-protein-coupled receptors, Fc receptors, and inflammatory adhesion molecules
(Ley, 2002). Finally, chemokines are responsible for changes in neutrophil morphology, from a spherical to a
polarized motile shape with a leading edge and a uropod that concentrates a great number of adhesion
molecules, known to be required for PMN rolling and chemotaxis (del Pozo et al., 1995).
Activation of neutrophils can be achieved with nanomolar concentrations of phorbol esters in vitro
(Patarroyo et al., 1985). Such type of stimulation can lead to rapid mobilization of different subsets
neutrophil cytoplasmic granules, as well as, secretory vesicles for exocytosis (Kjeldsen et al., 1992), whereas
similar concentrations of fMLP can only induce discharge of secretory vesicles (Sengelov et al., 1993).
Binding of chemoattractants to their corresponding G-protein-coupled receptors leads to the activation of
phospholipase C, which in turns, cleaves phosphoinositol (4,5) biphosphate (PIP2) into inositol 1, 4, 5-
triphosphate (IP3) and diacylglycerol (DAG). IP3 induces elevation in intracellular Ca2+ levels, whereas
DAG activates protein kinase C (PKC). Increase in intracellular Ca2+ levels results in integrin activation via
inside-out signaling (Altieri et al., 1992; van Kooyk et al., 1993) and when Ca2+ reaches concentrations as
high as 40-50 nM, it induces complete release of secretory vesicles from neutrophils (Nüsse et al., 1998).
Apparently, neutrophil degranulation can also be triggered by elevations in intracellular Ca2+ levels,
especially after L-selectin and aMb2 integrin engagement (Ng-Sikorski et al., 1991; Laudanna et al., 1994). In
addition, neutrophil attachment and rolling to cytokine-stimulated vascular endothelium can promote
translocation of secretory vesicles to the plasma membrane, thus providing the neutrophil surface with
adhesion receptors, including the aMb2 integrin (Carlos and Harlan, 1994; Borregaard et al., 1994).
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Granulopoiesis and subsets of neutrophil granules
Neutrophil granules are formed during different stages of maturation of myeloid cells in the bone
marrow. Granule formation (granulopoiesis) is a result of a homotypic fusion between identical immature
transport vesicles that bud off from the Golgi apparatus, a process that begins in early promyelocytes
(Bainton and Farquhar, 1966; Bainton et al., 1971). Proteins of different granule subsets are synthesized at
different stages of maturation of neutrophil precursors and proteins of the same subset of granules are
produced simultaneously (Borregaard et al., 1995; Le Cabec et al., 1996) (Figure 4). Several transcription
factors are involved in controlling granule protein expression in neutrophils, including GATA-1, with a site
found in the genes of the aM subunit of aMb2 integrin and lactoferrin, and c-Myb, with potential sites in the
genes of elastase, myeloperoxidase, proteinase-3, and azurocidin (Borregaard and Cowland, 1997). Protein
expression and granule formation defects have been observed in acute myeloid leukemia cells, where the
normal cell differentiation program is disrupted. Neutrophil granules show great differences in size, density,
protein content, as well as tendency for extracellular secretion.
Figure 4. Biosynthetic windows of granules and granule proteins. MB, myeloblast; PM, promyelocyte; MC,
myelocyte; MM, metamyelocyte; BC, band cell; PMN, polymorphonuclear neutrophil. Granule proteins: MPO,
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myeloperoxidase; PR-3, proteinase 3; LF, lactoferrin, AP, alkaline phosphatase; NGAL, neutrophil gelatinase-
associated lipocalin (Modified from Faurschou and Borregaard, 2003).
To date, four types of granules have been detected in neutrophils: the “primary or azurophilic
granules”, “secondary or specific” granules, “tertiary or gelatinase” granules, and “secretory” vesicles,
defined by their content in myeloperoxidase (MPO), lactoferrin (LF), gelatinase B (MMP-9), and latent
alkaline phosphatase, respectively. Azurophilic granules appear in the promyelocytic phase, whereas the rest
of the granule subsets, in the myelocytic or later stages (Figure 4). Neutrophil degranulation results in the
release of granule-containing MMPs which are thought to facilitate neutrophil transmigration through the
vascular basement membrane (Delclaux et al., 1996). Both in vitro and in vivo data describe secretory
vesicles as the first (fastest) granules to be released, followed by gelatinase granules, and last, the specific
granules (Sengelov et al., 1993). Gelatinase granules can be released in the presence of intracellular Ca2+, at
levels above 50 nM plus ionomycin; specific granules, at levels as high as 1µM; and azurophilic granules,
only in the presence of extreme values (Nüsse et al., 1998) (see Table 4). Neutrophil granule subsets undergo
partial exocytosis once they are in contact with ECM components, thus releasing matrix-degrading enzymes,
collagenases and serine proteases to facilitate neutrophil migration.
Exocytosis of both specific and azurophilic granules can also be achieved via disruption of
cytoskeleton contacts with cytochalasin B, whereas stimulation of various plasma membrane receptors, such
as integrins results in the release of the majority of secretory vesicles (Sengelov et al., 1993, Nüsse et al.,
1998). Rho GTPases, including Rac1, Rac2, and Cdc42 have been suggested to play an important role in the
regulation of primary granule exocytosis in neutrophils. Studies from knockout mice also suggested that Vav
proteins can promote b2 integrin-association to Rho GTPases and regulate G protein-coupled receptor-
induced signaling events which are essential for leukocyte adhesion and phagocytosis (Gakidis et al., 2004).
When neutrophils encounter with bacteria, they activate antimicrobial systems by the release of
granule components to the phagocytic vacuole or extracellularly (Joiner et al., 1989). Cytoplasmic granules
are discharged in a targeted and regulated manner, a mechanism that enables transformation of neutrophils
from passive circulating cells to potent effector cells of the innate immunity. The granule components target
bacteria by different ways: (1) disruption of their membrane (defensins, BPI, lactoferrin, and lysosyme); (2)
interference with their iron-dependent metabolic pathway (NGAL and lactoferrin); (3) generation of oxygen
species (MPO and cytochrome b558); and (4) by induction of chemotaxis of CD4+ and CD8+ T lymphocytes
(defensins, azurocidin, and hCAP-18) (reviewed in Faurschou and Borregaard, 2003).
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GRANULES
/VESICLES
MEMBRANE MATRIX
Azurophilic
granules
CD63 (granulophysin),
CD68 (macrophage associated
antigen), Stomatin, Presenilin 1,
Vascular-type H+-ATPase
Cathepsins, Elastase, Proteinase 3,
Defensins, Sialidase, Azurocidin,
Lysosyme, Ubiquitin-protein, BPI,
MPO, Acid b-glycerophosphatase, a-
Mannosidase, b-glucuronidase, Acid
mucopolysaccharide, a1-antitrypsin,
N-acetyl-b-glucosaminidase, b-
glycerophosphatase, phospholipase A2
Specific
granules
BAP31, aMb2, uPAR, fMLP-R,
Thrombospondin-R, Laminin-R,
Vitronectin-R, Fibronectin-R, TNF-
R, Cytochrome b558, Rap-1, Rap-2,
MT6-MMP (MMP-25), Stomatin,
CD15 antigens, NB1 antigen,
CD15, CD66, CD67, VAMP-2,
SCAMP, 19-kD/155-kD proteins,
SNAP-23/-25, G-proteina-subunit
Glutaminase, MRP-14, MMP-9, uPA,
MMP-8, Lactoferrin, NGAL, CRISP-
3, Heparanase, Histaminase, Sialidase
Histaminase, Lysosyme, b2-
microglobulin, hCAP-18, Vitamin
B12-binding protein, Transcobalamin-
I, phospholipase A2
Gelatinase
granules
aMb2, aXb2, uPAR, fMLP-R,
Vascular-type H+-ATPase, SCAMP,
Cytochrome b558, MT6-MMP
(MMP-25), NRAMP-1, VAMP-2,
SNAP-23/-25, Diacylglycerol-
deacylating enzyme
MMP-9, MRP-14,
uPA,
Lysosyme,
b2-microglobulin,
CRISP-3,
Acetyltransferase
Secretory
vesicles
aMb2, Alkaline phosphatase,
Cytochrome b558, MT6-MMP,
fMLP-R, uPAR, C1q-R,
Vascular-type H+-ATPase,
CD10, CD13, CD14, CD16, CD35,
CD45, DAF, SCAMP, VAMP-2
Azurocidin, MRP-14,
Plasma proteins (tetranectin,
latent alkaline phosphatase, etc.)
Other
Compartments
MVB
MLC
PM (markers)
aMb2
Alkaline phosphatase
Cytochrome b558
LAMP-2/LAMP-1 CI-M6P receptor
LAMP-2/LAMP-1
HLA-1, L-selectin
M6P-glycoproteins
M6P-glycoproteins
Table 4. Granule- and secretory vesicle-content of resting neutrophils. Other compartments are also mentioned.
MMP, matrix metalloproteinase; MT-MMP, membrane-type MMP; BPI, Bactericidal/permeability-increasing protein;
MPO, myeloperoxidase; CRISP, cystein-rich secretory protein; HBP, heparin-binding protein; MVB, multivesicular
bodies; MLC, multilaminar compartments, LAMP, lysosome-associated membrane proteins; M6P, mannose-6-
phosphate, HLA, human leukocyte antigen; hCAP, human cathelicidin protein-18; uPAR, urokinase-type plasminogen
activator receptor; NGAL, neutrophil gelatinase-associated lipocalin; DAF, decay-accelarating protein; NRAMP-1,
natural resistance-associated macrophage protein-1; SCAMP, secretory carrier membrane protein; SNAP, synaptosome-
associated protein, MRP, myeloid-related protein-14; PM, plasma membrane (Table modified from Borregaard and
Cowland, 1997).
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INTEGRINS AND THEIR LIGANDS
Adhesion receptors, later called integrins were first described in the mid 1980’s (Patarroyo et al.,
1985a,b). In 1986, the term “integrin” was first designated to describe a protein complex that was involved in
the transmembrane linkage between the ECM (fibronectin) and the cytoskeleton (actin) (Tamkun et al.,
1986). Soon after, other homologous and structurally related proteins were discovered, thus forming a family
of cell surface receptors. Integrins have been detected in all metazoans, including sponges and cnidaria, and
organisms as diverse as nematodes and flies (Hynes and Zhao, 2000). In vertebrates, integrins play important
roles in certain cell-cell adhesions and in the activation of various signaling pathways. However, no
homologs of integrins are present in prokaryotes, plants, or fungi (Whittaker and Hynes, 2002). Integrins are
major heterodimeric receptors which are involved in many cell-cell and cell-ECM interactions (reviewed in
Hynes, 2002). They are type I transmembrane glycoproteins present on the surfaces of various cells,
consisting of two subunits designated a and b that are noncovalently linked to each other. They have a large
extracellular domain and a single transmembrane domain, followed by a relatively short cytoplasmic domain
(Tuckwell and Humphries, 1993). In mammals, 18 a and 8 b subunits assemble to produce at least 24
distinct heterodimers identified to date, each of which is capable of interacting specifically with membrane-
bound, ECM, or soluble protein ligands (reviewed by Hemler, 1990). Figure 2 depicts the complete list of the
integrin receptor family with all the possible a- and b-subunit associations.
The integrin family is divided into four major subgroups, based on ligand specificity and cellular
expression: b1 (CD29) integrins (or very late antigens (VLA)), b2 (CD18) integrins (or leukocyte-specific
integrins), b3 (CD61) integrins (or cytoadhesins), and b7 (Springer, 1990; Gahmberg et al., 1997; Harris et
al., 2000). Integrins bind to their ligands in a divalent-cation-dependent manner (reviewed in Kanazashi et
al., 1997; Plow et al., 2000).
Figure 2. Schematic picture of the
integrin family. 8 b subunits can
associate with 18 a subunits to form
24 distinct integrin heterodimers, of
which 9 out of 18 have an I
(inserted) domain. The integrin a-
subunits that lack or contain an I
domain are shown as white and
purple circles, respectively. The b-
subunits are shown in black.
Integrins that recognize RGD-motif
containing ligands are depicted in a
green triangle. The leukocyte-
specific integrins are within a
yellow triangle. Figure modified
from Hynes, 2002.
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The b1 integrins comprise a large family of receptors which are involved in mediating cell adhesion
to ECM proteins, such as collagen, laminin, vitronectin, and fibronectin. They are expressed in almost all
types of cells, where they perform multiple functions (Hemler, 1990; Tuckwell and Humphries, 1993;
Hynes, 2002). The various combinations of different a (a1-a11) subunits and a common b1 subunit increase
the diversity of the integrin receptors. Among these integrin heterodimers, a1b1 (VLA-1), a2b1 (VLA-2),
a3b1 (VLA-3), a4b1 (VLA-4), a5b1 (VLA-5), a6b1 (VLA-6) are expressed in leukocytes (reviewed in
Hemler, 1990). One important example is a4b1 which has been shown to be involved in tethering, rolling,
firm adhesion, and transendothelial migration of leukocytes across the endothelium by interacting with
components of the ECM, such as fibronectin, and the vascular cell adhesion molecule-1 (VCAM-1, CD106)
that is present on the surface of endothelial cells (Elices et al., 1990; Adams and Lobb, 1999). In addition,
a4b1 has been reported to mediate homophilic interactions with a4b7 (Altevogt et al., 1995), an integrin
which is known to recognize several molecules, including MadCAM-1, VCAM-1, and fibronectin (Berlin et
al., 1993) (see Table 1). Although low levels have been detected in blood circulating leukocytes, b1 integrin
receptors can be rapidly upregulated after leukocyte migration through the vascular endothelium. Unlike b2
integrins, additional signaling is required for upregulation of b1-integrin expression. This can be achieved by
signaling that is generated either by chemotactic molecules or by engagement of b2 integrins (for example, by
antibody-induced cross-linking of b2 integrins) (Werr et al., 2000a). Furthermore, induction of b1-integrin
expression on the surface of neutrophils strongly correlates with neutrophil transendothelial migration in in
vitro (Roussel and Gingras, 1997) and in vivo (Werr et al., 1998; Werr et al., 2000b) models that mimic
neutrophil extravasation.
The b3 integrin family includes the ubiquitous aVb3 integrin, which is a receptor recognizing many
ECM components, and aIIbb3, the major platelet integrin. aVb3 is found mainly in non-hematopoietic cells,
whereas aIIbb3 is enriched in platelets. Previous studies confirmed the importance of b3 integrins in leukocyte
adhesion via binding to PECAM-1 (CD31) (Piali et al., 1995), as well as in activation and migration of these
cells across endothelial cells and epithelial monolayers (Lawson and Maxfield, 1995; Brown, 1990; Rainger
et al., 1999), possibly via binding to the integrin-associated protein, IAP or CD47 (Lindberg et al., 1993).
IAP was first isolated as a complex with both aVb3 and aIIbb3 integrins (Brown and Frazier, 2001), as well as
with aVb5 and a2b1. Recently, IAP and the aVb3 integrin were also shown to bind thrombospondin (TSP-1)
via its RGD motif, thus increasing both aVb3-mediated spreading of human melanoma cells and a2b1-
mediated chemotaxis of smooth muscle cells (Wang and Frazier, 1998).
The subfamily of integrins that mediate leukocyte firm adhesion to the endothelium, includes four
members named either b2 integrins or according to the cluster of differentiation antigen nomenclature,
CD11/CD18 integrins. These leukocyte specific integrins include: aLb2 (LFA-1, CD11a/CD18), aMb2 (Mac-
1, CD11b/CD18, CR3), aXb2 (p150,95, CD11c/CD18), and aDb2 (CD11d/CD18). The b2 integrins are also
known to promote interactions of leukocytes with endothelial cells (during firm adhesion and
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transmigration), with other leukocytes, as well as with cell-surface bound opsonins on invading bacteria and
rejected or hypoxic tissues (Arnaout et al., 1983; Hogg, 1989; Arnaout, 1990a; Springer, 1990; Gahmberg et
al., 1990).
The b2 integrins were first purified in the late 1970’s from mouse macrophages or human
monocytes and lymphocytes (Milstein et al., 1979; Davignon et al., 1981), which affected several
lymphocyte functions, but they were not known to be adhesion proteins. Convincing proof for their adhesive
nature was obtained by inducing adhesion using phorbol esters followed by inhibition with antibodies
recognising the b2-chain (Patarroyo et al., 1995a,b; Rothlein and Springer, 1986). Since the recognition of
the integrin receptor family over the past 20 years (Hynes, 1987), enormous progress has been done in
elucidating the integrin structure and function. Currently, integrins are the best-understood family of cell
adhesion receptors.
The aLb2 integrin is primarily expressed in lymphocytes but also found in all other leukocytes. It was
first described on murine and human lymphocytes by using monoclonal antibodies (mAbs) that could inhibit
both cytotoxic T cell-mediated killing and T cell proliferation (Davignon et al., 1981; Sanchez-Madrid et al.,
1982). Later, aLb2 was shown to play an essential role in leukocyte adhesion and migration across the
endothelium by its ability to bind to several intracellular adhesion molecules (ICAMs), especially ICAM-1
which is present on the surface of endothelial cells, to E-selectin, and to collagen type I (Kotovuori et al.,
1993; Garnotel et al., 1995; Gahmberg, 1997). Initiation of an immune response requires the formation of the
immunological synapse between T cells and antigen-presenting cells (APCs). This process involves the
association of aLb2 integrin with ICAM-1 (Bachmann et al., 1997), ICAM-3 (Bleijs et al., 2000), and other
adhesion molecules, aligning the plasma membranes of the two cells in proximity to each other (Grakoui et
al., 1999). Recent reports point out the importance of aLb2 in organ transplant and treatment of autoimmune
diseases, since mAbs directed against it substantially increased graft survival in several animal models
(Poston et al., 2000; Nicolls et al., 2002), and impaired the symptoms of psoriasis in clinical trials (Gottlieb
and Bos, 2002).
The aMb2 integrin is expressed on cells of the myeloid lineage, such as granulocytes, monocytes, and
macrophages, and it is capable of mediating many of the proinflammatory functions in these cells (Dana et
al., 1991). It binds to a broad spectrum of ligands, such as membrane-anchored ICAMs (ICAM-1, -2, and –4)
(reviewed in Gahmberg et al, 1997; Gahmberg, 1997), and to several soluble ligands, including the
complement fragment iC3b, fibrinogen, factor X, heparin, E-selectin (Crutchfield et al., 2000), bacterial
lipopolysaccharide (LPS) (Wright and Jong, 1986), urokinase-type plasminogen activator receptor (uPAR)
(Pluskota et al., 2003), catalase (Davis, 1992), myeloperoxidase (Johansson et al., 1997), junctional adhesion
molecule 3 (JAM-3), and proteinases, such as proteinase 3, cathepsin G, neutrophil elastase (Cai and Wright,
1996), various ECM proteins (Yakubenko et al., 2002 and references therein) (see Table 1).
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ADHESION
 MOLECULES
LIGANDS LOCALIZATION
Integrins
b2  integrins
aLb2 (LFA-1)
aMb2 (Mac-1)
ICAM1-5, LRP
ICAMs, E-selectin, iC3b, FG, Factor
 X, heparin, uPAR, Thy-1, LRP,
FN, NIF, JAM-C, NE, GPIba, Cyr61
Lymphocytes
Granulocytes/monocytes
aXb2 (p150,95)
aDb2
ICAM-1, iC3b, FN, FG, CD23
ICAM-1/-3, VCAM-1
Macrophages
Macrophages
b7 integrins
a4b7
aEb7
VCAM-1, MAdCAM-1, FN
E-cadherin
Lymphocytes
(lymph nodes)
Lymphocytes
(intraepithelia)
b1  integrins
a1b1 (VLA-1)
a2b1 (VLA-2)
a3b1 (VLA-3)
Collagens, Laminin-1
Collagens, Laminin-1, MMP-1
Laminins, TSP
Lymphocytes
Lymphocytes
Lymphocytes
a4b1 (VLA-4)
a5b1 (VLA-5)
a6/7b1 (VLA-6/-7)
VCAM-1, FN, OP, TSP
FN, TSP, ADAMs, endostatin
Laminins
Lymphocytes
Lymphocytes
Lymphocytes
a8b1 (VLA-8)
a9b1 (VLA-9)
a10b1 (VLA-10)
a11b1 (VLA-11)
FN, VN, OP, TN-C, NN, LAP
VCAM-1, TN-C, OP
Collagen type II
Collagen type I
Mesangial/myofibroblast
Neutrophils
Chondrocytes
Chondrocytes
b3  integrins
aVb3 CD31, FN, VN, TSP, vWF, TN-C, OP,
thrombin, agrin, fibrillin, canstatin, tum,
MMP-2, ADAMs, BSP, Thy1
Macrophages
b5  integrins
aVb5 VN, OP, HIV tat, BSP, LAP, canstatin Endothelial cells
Selectins
L-selectin (CD62L)
E-selectin (CD62E)
P-selectin (CD62P)
E-/-P selectins, GlyCAM-1, CD14,
MAdCAM-1, CD34, sLeX, PSGL-1
ESL-1, sLeX, PSGL-1, L-selectin,
CLA, SSEA-1
PSGL-1, sLeX, CD24
All leukocytes
Endothelial cells
Endothelial/platelets
Members of IgSF
ICAM-1 (CD54)
ICAM-2 (CD102)
ICAM-3 (CD50)
ICAM-4
aL/M/Xb2, MMP-9
aL/Mb2
aL/Db2
aL/M/Xb2, a4b1, aVb1,3,5, aIIbb3
Endothelium/monocytes
Endothelium/leukocytes
Endothelium/leukocytes
Erythrocytes
ICAM-5
VCAM-1 (CD106)
PECAM-1 (CD31)
MAdCAM-1
aLb2
a4b1, a4b7, aDb2
PECAM-1, aVb3
a4b7, L-selectin, a4b1
Neurons
Endothelial cells
Endothelium/leukocytes
Endothelium (intestine)
Table 1. Molecules involved in adhesive interactions between leukocytes and the vascular endothelium. IgSF,
immunoglobulin superfamily; TSP, thrombospondin; OP, osteopontin; TN, tenascin; NE, neutrophil elastase; NN,
nephronectin; LAP, TGFb latency associated protein, iC3b, inactivated complement component 3b; can, canstatin; tum,
tumstatin; BSP, bone sialic protein, LRP, LDL-related protein; NIF, neutrophil inhibitory factor; JAM-C, junctional
adhesive molecule-C, GPIba, glycoprotein Iba; Thy1, thymus cell antigen 1.
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MAbs raised against the aMb2 integrin dramatically alleviated the degree of ischemia-reperfusion
injury in several animal models of phagocyte-dependent acute tissue injury (Vedder et al., 1988). aMb2-
integrin antibodies also inhibited the accumulation of phagocytes in damaged tissues and their interaction
with the complement iC3b, thus preventing development of insulin-diabetes mellitus in susceptible mouse
strains (Hutchings et al., 1990). Antibody treatment was also found to be successful in models of
experimental autoimmune encephalomyelitis (Huitinga et al., 1993) and colitis (Palmen et al., 1995) by
inhibiting the accumulation of neutrophils and monocytes to the inflammatory sites. Finally, anti-aM mAb
therapy led to strong attenuation of the severity of disease in two models of arthritis (Taylor et al., 1996; de
Fougerolles et al., 2000), and showed reduced injury in several ischemia-reperfusion models by blocking
leukocyte-endothelial cell interactions (Cornejo et al., 1997).
The aXb2 integrin is mainly expressed on tissue macrophages, and is a marker for hairy cell
leukemia. It is also expressed, at lower levels, on dendritic cells, granulocytes, natural killer (NK) cells,
lymphoid cells lines and populations of activated T and B cells (Cabanas, 1999). aXb2 binds to ICAM-1,
iC3b, fibrinogen, and type I collagen (Garnotel et al., 2000). The most recently discovered b2 integrin, aDb2
is primarily found on monocytes, macrophages, oesinophils and other leukocytes, and mediates binding to
ICAM-3 and VCAM-1 (van der Vieren, 1995). This interaction may contribute to the homing and keeping
leukocytes in certain tissues.
Structure and function of leukocyte b2 integrins
The structural characteristics and functional roles of leukocyte b2 integrins have been extensively
reviewed recently (Gahmberg et al., 1997; Arnaout, 2002; Shimaoka et al., 2002; Takagi and Springer,
2002). The b2 integrins (aLb2, aMb2, aXb2, and aDb2) consist of a- (1063, 1137, 1144, and 1084 residues,
respectively) and b- (747 residues) subunits (Figure 3A). The extracellular domains of all b2-integrin
subunits contain several potential N-glycosylation sites: 12 in aL, 19 in aM, 8 in aX, 11 in aD, and 6 in the b-
chain (reviewed in Gahmberg et al., 1997) and the structures of the oligosaccharides have been determined
(Asada et al., 1991). Divalent cations are essential for integrin functions by regulating the integrin structure
in a state in which they increase or suppress binding to physiological ligands (reviewed in Plow et al., 2000).
To date, the primary structures of all four b2 integrin a- and b-subunits have been described by molecular
cloning (Corbi et al., 1987; Arnaout, 1988; van der Vieren et al., 1995).
Sequence analysis of the a-subunits showed approximately 60-65 % homology between the aM (170
kDa), aX (150 kDa), and aD (155 kDa) subunits, and about 35 % of homology to aL (180 kDa). The aL, aM,
aX, and aD subunits are encoded by three distinct genes that are all clustered on chromosome 16 (Marlin et
al., 1986; Arnaout et al., 1988). The b2 gene is on chromosome 21 (Suomalainen et al., 1986; Marlin et al.,
1986). Each integrin a-subunit contains seven, 60- amino-acid long, homologous segments in the amino-
terminal region, and with resemblance to a domain present in the trimeric G protein b-subunit, which are
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predicted to fold into a seven-bladed b-propeller domain (Tuckwell et al., 1994; Springer, 1997). Along with
the predicted I-like domain (bA) from the b-subunit, they both interact to form the “head” of the integrin
(Figure 3B). Each a-subunit contains three characteristic EF-hand-like divalent cation-binding sites within
the b-propeller sheets 5-7, with resemblance to metal-binding motifs DXXDXXXD present in several
calcium-binding proteins, including calmodulin and parvalbumin (Arnaout, 1990b).
Half of all integrin a-subunits contain an additional, 200-amino-acid long, I domain which is
inserted between the propeller b-sheets 2 and 3 (Arnaout, 1988; Michishita et al., 1993; Diamond et al.,
1993a; Springer, 1997), and is homologous to a plasma glycoprotein von Willebrand factor (Colombatti and
Bonaldo, 1991). The three-dimensional architecture of the extracellular domains of the integrin a- and b-
subunits has been revealed by crystallization, electron microscopy, and nuclear magnetic resonance (NMR)
(Xiong et al., 2001, 2002; Beglova et al., 2002; Takagi et al., 2002). Based on the crystal structure of the
extracellular domains of aVb3, it has been predicted that the I domain lies on top of the b-propeller domain
(Springer, 1997) (Figure 3C).
The I domain plays an essential role in ligand binding (Diamond et al., 1993a; Michishita et al.,
1993; Colombatti et al., 1993), with a partial contribution from the b-propeller (Stanley et al., 1994;
Dickeson et al., 1997). Also, the EF-hand-like repeats indirectly participate in ligand binding (Xiong et al.,
2001). This conclusion is strongly supported by mAb-mapping, mutation, and I-domain deletion studies
(Diamond et al., 1993; Randi and Hogg, 1994; Leitinger and Hogg, 2000a). The crystal structures of aL (Qu
and Leahy, 1995), aM (Lee et al., 1995), a2 (Emsley et al., 1997; 2000), and a1 (Salminen et al., 1999) I
domains have been solved. They all adopt a classical dinucleotide-binding (Rossmann) fold, with five
parallel and one antiparallel b-strand in the center, surrounded by seven a-helices, and a divalent cation-
binding site, referred to as the Metal Ion-Dependent Adhesion Site (MIDAS) at the apex of the I domain.
The binding of a divalent cation, such as Mg+2 or Mn+2, is coordinated by oxygen-containing side chains
from five amino acids of the I domain and a predicted sixth residue provided by the ligand (Lee et al., 1995;
Emsley et al., 2000). The metal cations and MIDAS ion, located at the bottom of the b-propeller and in the I
domain of the a-subunit, respectively, are reported to affect the stability of the integrin’s structure. For
example, the MIDAS cation in the I domain increases the integrin’s resistance to thermal or chemical
denaturation and has the ability to directly activate integrins (reviewed in Xiong et al., 2003). Mutational
studies have shown the importance of these divalent cations in ligand binding (Kamata et al., 1995a;
McGuire and Bajt, 1995). Indeed, inhibition of the integrin function is achieved by EDTA, which chelates
divalent cations (Altieri, 1991).
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Figure 3. Schematic structure of the leukocyte integrin. (A) represents the integrin’s primary structure, including
divalent cation-binding sites (Mg+2 as red and Ca+2 as grey stars). (B and C) are schematic representations of the bent
(inactive) and strainghtened (active) conformations of the integrin, respectively. The arrangement of domains is based
on the three-dimensional crystal structure of aVb3 integrin, with an I domain added between the 2nd and 3rd b-propeller
repeats. Each domain is coloured as in A. I-d, I-domain; I-EGF, integrin-epidermal growth factor domain; PSI,
plexin/semaphorin/integrin; b-TM, b-tail domain.
The common b2-subunit of leukocyte integrins is different from their corresponding a-subunits, but
is homologous to b1 and b7 by 46 %. An interesting feature of the primary sequence of the b-subunit is a
carboxy-terminal cysteine-rich repeat made of four EGF-like domains which lie below the hybrid domain
(Beglova et al., 2002). Another cysteine-rich region (seven cysteine residues) is located within the 54-amino
-acid long PSI domain (Bork et al., 1999) that lies amino-terminal to the hybrid domain, and named after its
sequence homology with plexins, semaphorins, and integrins. All together, 56 cysteine residues are present
in the b-subunit. These cysteine-rich regions are known to keep the integrin in its inactive conformation
(Zang and Springer, 2001). A sequence with a homology to the I-domain of the a-subunit is also found in the
amino-terminus of the integrin b-subunit and denoted the I-like domain. The I-like domain is 241 residues
long and contains a MIDAS motif (DXSXS), similar to that of the I-domain. Based on mutational studies,
the I-like domain (via a residue at position 243) is important in forming contacts with the a-subunit b-
propeller (via a residue at position 438) (Zang et al., 2000; Xiong et al., 2001) and with various ligands in
integrins which lack I domains (Goodman and Bajt, 1996). These contacts are essential for proper folding of
the integrin subunits (Huang et al., 1997; Huang and Springer, 1997). Additional contacts are known to be
formed between the a- and b-subunits: for example, (1) between the hybrid domains and the b-propeller,  (2)
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between the EGF3 and calf-1 domains, (3) between the EGF-4 and calf-2, and (4) between the b-subunit
transmembrane domain (bTM) and calf-2 (reviewed in Arnaout, 2002).
Loss of heteromerization of the integrin during biosynthesis caused by mutations in the gene
encoding the b-subunit resulted in reduced b2-integrin cell-surface expression and function on leukocytes,
leading to a rare human inherited disease, called leukocyte adhesion deficiency-I (LAD-I) (Anderson and
Springer, 1987; Arnaout, 1990a; Hogg and Bates, 2000). Expression of nonfunctional b2 integrins was also
observed in LAD-I patients carrying mutations in the MIDAS motif of the I-like domain in the b-subunit
(Hogg et al., 1999). Polymorphonuclear neutrophils (PMNs) and monocytes from LAD-I patients fail to
migrate through the vascular endothelium or become fully activated because of lack of adherence, actin
cytoskeleton rearrangement, and spreading on ICAM-1- or ECM-coated surfaces (Shappell et al., 1990). This
explains why LAD-I patients are exposed to life-threatening bacterial infections. The same phenotype was
observed in b2-integrin knockout mice (Scharffetter-Kochanek et al., 1998). In accordance to these results, a
study on the contribution of each subunit separately in adhesion or migration of cells showed that a-subunit-
expressing cells mediated adhesion and spreading on a variety of integrin ligands, but failed to support cell
migration. However, cells expressing only the b2-subunit showed a migratory phenotype and successfully
attached on a subset of integrin ligands but failed to spread on these ligands (Solovjov et al., 2005). In the I-
domain-containing integrins, ligand binding appears to be indirectly regulated by the I-like domain. High
resolution electron microscopic (EM) studies suggested that head separation of the integrin a- and b-subunits
was not triggered by ligand binding (Weisel et al., 1992; Du et al., 1993; Erb et al., 1997; Takagi et al.,
2002), and did not result in high affinity ligand binding by integrins (Luo et al., 2003). However, recent
studies provide evidence that loss of heterodimerization between the integrin TM domains increase ligand
binding affinity, whereas integrin valency or clustering remain unchanged (Luo et al., 2005).
The cytoplasmic tails of integrins are smaller in size (< 50 residues) than their extracellular domains
and are pivotal in regulating ligand binding and signaling function (Woodside et al., 2001). All a-chains
contain a conserved GFFKR motif proximal to the cell membrane (Williams et al., 1994). Truncation of
either one of the integrin tails can lead to a constitutively active receptor (O’Toole et al., 1994). Unlike b2
integrins which have a NPXF motif in their b-chain, the cytoplasmic domains of the rest of the integrin
family contain two conserved NPXY motifs (van Kooyk et al., 1998). Mutations of the threonine residues in
a conserved motif, SXXTT which is present in b1, b2, and b7 integrins (reviewed by Ylänne, 1998), decreased
leukocyte adhesion via inhibiting complex formation between aLb2 integrin and ICAM-1 (Hibbs et al.,
1991a, 1991b; Williams et al., 1994). These motifs may be important, not only in signaling, but also in
integrin endocytosis and localization (van Kooyk et al., 1998) (see below). Several reports support the idea
that association of the membrane proximal regions of the a and b subunit cytoplasmic domains is needed to
keep the integrin in its low affinity state (Hughes et al., 1996; Vallar et al., 1999; Lu et al., 2001a; Takagi et
al., 2001; Vinogradova et al., 2002). Eventually, disruption of the interacting sites between these two tails
leads to an active integrin.
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Structural features of the integrin I-domains alone or in association with their binding partners,
ICAMs have been recently documented (reviewed in Springer and Wang, 2004). Three distinct
conformations of the I domain have been reported, denoted closed, intermediate, and open, which reflect the
low, intermediate, and high affinity state of the integrin for ligand binding, respectively (Shimaoka et al.,
2003). The first crystal structure of aL I domain in a complex with ICAM-1 was determined at 3.3-Å
resolution (Shimaoka et al., 2003). This structure revealed the open ligand binding conformation of the I
domain, bearing a Mg+2 in its MIDAS site which directly coordinates a glutamic acid (Glu-34) residue in
ICAM-1.
Integrin-Ligand
interactions
Integrin and Ligand
binding sites
Method References
aLb2-ICAM-1 MIDAS-D1 (Glu34) X-ray Shimaoka et al., 2003
aLb2-ICAM-2 MIDAS-D1 (Glu37) Mutagenesis Casasnovas et al., 1999
aLb2-ICAM-3 MIDAS-D1 (Glu37) X-ray Song et al., 2005
aLb2-ICAM-4 I-domain-D1 (W19,77,93
                       ; L80; R97) Mutagenesis Hermand et al., 2004
aMb2-ICAM-4 I-domain-D1 (W19,77,93
;L80;R97)
               -D2(E151;T154)
Mutagenesis Hermand et al., 2004
aIIbb3-ICAM-4 unknown -D1 (Q30,36;G3
2;K33;W77) & D2 (E151) Mutagenesis
Hermand et al., 2004
aVb3-ICAM-4 unknown -D1 (R52,97;Y6
9;D73;L80;K33;W66,77)
                -D2 (E151;T154)
Mutagenesis Hermand et al., 2004
aVb1/5-ICAM-4 unknown -D1 (W19,66;F1
8;V20;R92,97;A94;T94,S96)
                -D2 (K118)
Mutagenesis Mankelow et al., 2004
aMb2/aXb2-FG I-domain-P1 (g400-411) &
                P2 (g 377-395) sites Mutagenesis
Ugarova & Yakubenko,
2001
aVb3-FN I-like domain-
                      FNIII D10 (RGD)
X-ray
EM
Xiong et al., 2002
Adair et al., 2005
aVb3-ADAM-15 I-domain-RGD Mutagenesis Zhang et al., 1998
aIIbb3-FN b-propeller -
                  FNIII D9-10 (RGD)
Mutagenesis Kauf et al., 2001
Xiao et al., 2004
aIIbb3-FG b-propeller/I-like domain-
              C-terminal (g 400-411) Mutagenesis
Kamata et al., 2001
Xiao et al., 2004
a1b1/a2b1-Laminin a-subunits-a2 chain short arm Blocking Abs Colognato et al., 1997
a2b1-collagen MIDAS-
               G(F/L/M)OGE(131)R X-ray Emsley et al., 2000
a4b1-FN a4b1-FN14 (PRARI) Mutagenesis Sharma et al., 1999
a4b1-FN b1 chain (ID(130)S)-
                     CS1 (EILDVPST)
Blocking
peptides Guan and Hynes, 1990
a4b1-VCAM-1 b1 chain (ID(130)S)-
                           D1 (C-D loop)
X-ray
Mutagenesis Kamata et al., 1995b
a5b1-FN b-propeller/I-like domain-
                          FN7-10 (RGD) EM Takagi et al., 2003
aEb7-E-Cadherin MIDAS-Glu31 Mutagenesis Higgins et al., 2000
Table 2. Integrin-ligand interaction sites. ICAM, intercellular adhesion molecule; D1, domain 1; Abs, antibodies; FN,
fibronectin; FG, fibrinogen; RGD, Arg-Gly-Asp; VCAM, vascular cell adhesion molecule. Important amino acids for
binding are marked in bold.
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More recently, another crystal structure of aL I domain in complex with ICAM-3 (Glu-37) has been
determined at a resolution as high as 1.65-Å (Song et al., 2005). These structures allow us to conclude that
the binding of ICAMs onto the I domains of integrins is mediated by a common docking mechanism. Other
techniques utilized to characterise the association between leukocyte integrins and their ligands, include EM,
NMR, mAb mapping, and mutagenesis of either ligand or receptor. Several other integrin complexes and
their precise mechanism of association have been determined (see Table 2).
Activation of leukocyte b2 integrins
The term ”activation” applied to integrins describes changes that are required in order to increase
ligand binding affinity, whereas activation of signaling receptors describes changes that result in enhanced
signal transduction mediated through ligand binding (reviewed in Calderwood, 2004). Four levels of integrin
signaling have been theoretically described: “inside-out”, “outside-in”, “anchorage”, in which integrins
anchor to the cytoskeleton; and “clustering”, in which integrins become clustered to stabilize adhesion.
Intensive mutagenesis and EM studies have revealed that both integrin activation and signaling are
mediated by conformational chances which occur bi-directionally, from the cytoplasmic domains to the
headpiece of the integrin (a process termed “inside-out”) and vice-versa (a process termed “outside-in”)
(reviewed in Lub et al., 1995; Liddington and Ginsberg, 2002; Shimaoka et al., 2002). These two processes
play an important role during cell proliferation (van Seventer et al., 1990) or in prevention of cell apoptosis
(Koopman et al., 1994).
A great number of cell surface receptors and integrin-associated proteins are known to be involved in
signaling events which are important in regulating the integrin affinity. The “inside-out” signals can be
initiated via stimulation of other cell surface receptors, including the tyrosine kinase-coupled T cell receptors
(TCR) or G protein-coupled chemokine receptors (Dustin and Springer, 1989; Lollo et al., 1993; Constantin
et al., 2000) and CD44 (Vermot-Desroches et al., 1995). Signals mediated by these receptors are thought to
modulate aLb2 integrin cytoplasmic tail-mediated triggering of enhanced adhesiveness in the extracellular
domain (O’Rourke et al., 1998; van Kooyk and Figdor, 1993). Increased integrin adhesiveness by inside-out
signals allows circulating leukocytes to strongly attach to the endothelium or to interact with antigen-
presenting cells (APCs; Springer, 1995; Grakoui et al., 1999). However, the mechanism involved in inducing
a high affinity state of aLb2 has remained poorly understood. Cross-talk of b2 integrins with ICAM-derived
peptides (Li et al., 1993, 1995), ICAMs (Bleijs et al., 2000), other integrins (Imhof et al., 1997; Chan et al.,
2000), selectins (Ruchaud-Sparagano et al., 2000) selectin ligands (Evangelista et al., 1999), PECAM-1
(Piali et al., 1993), and other cell surface molecules (Petty and Todd, 1996; Porter and Hogg, 1998) can
occur to modulate integrin function. For example, there is cross-talk between b2 integrins and several other
membrane-associated proteins, including a4b1 integrin, urokinase plasminogen activator receptor (uPAR),
IAP, and members of the tetraspan protein family (reviewed in Worthylake and Burridge, 2001). For
example, the ECM protein, TSP-1 binds to IAP and avb3 integrin through two different binding sites,
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resulting in increased intracellular signaling mediated via the avb3. This event has been shown to be
important in T cell adherence and activation (Reinhold et al., 1999), demonstrating that association of
integral membrane proteins in cis with integrins can have a strong effect on intracellular signaling. To date,
several other associations between integrins and other cell-surface receptors have been identified (Table 3).
Also, engagement of a4b1 integrin or L-selectin has been reported to induce adhesiveness of both aLb2 and
aMb2 integrins for ICAM or activated endothelial cells, an event mediated by increases in actin
polymerisation, as well as by integrin/selectin clustering (Simon et al., 1999; Chan et al., 2000).
Activation by signals within the cells leads either to an active conformation (extended conformation,
high affinity state) or clustering (high avidity state) of the integrin, both necessary for increased ligand
binding (reviewed in Zell et al., 1999). It has been reported that association between the a- and b-
cytoplasmic domains restricts the integrin in its inactive (bent conformation, low affinity state; Figure 3B)
conformation (Takagi et al., 2002). Dissociation of these domains, mediated by intracellular signals, induced
a switchblade-like opening of the integrin extracellular domains to an extended conformation (Figure 3C)
(Takagi et al., 2001; Vinogradova et al., 2002). Mutagenesis (Lu and Springer, 1997) and fluorescence
resonance energy transfer (FRET) (Kim et al., 2003) studies also provides evidence for conformational
changes occuring in the cytoplasmic tails during physiological activation. The extended conformation
describes an open conformation of the headpiece which corresponds to the high affinity state of the integrin
as demonstrated by NMR (Beglova et al., 2002) and EM studies (Takagi et al., 2002).
The cytoplasmic regions of aLb2 have been reported to modulate cell adhesion. Truncation of the b2
cytoplasmic domain or mutations performed in that region (T758TT/AAA), both abolished adhesion of COS
cells to ICAM-1 (Hibbs et al., 1991a). The TTT motif can be phosphorylated (Fagerholm et al., 2004) and
mutations of the motif affects adhesion, actin reorganization, and cell spreading (Peter and O’Toole, 1995).
Conformational changes in aLb2 are also thought to be induced after association of the integrin cytoplasmic
tails with talin, or adaptor proteins, such as cytohesin-1 (Nagel et al., 1998; Hmama et al., 1999; Geiger et
al., 2000). Talin head is known to bind to the b-chain cytoplasmic domain, thus triggering the separation of
the two cytoplasmic domains (Calderwood and Ginsberg, 2003, Vinogradova et al., 2004). Also, recruitment
of cytohesin-1 to the plasma membrane and its association with aLb2 increases adhesion to ICAM-1
(Kolanus et al., 1996). Recent data demonstrate that cytohesin-1, phosphatidylinositol 3(-OH) kinase
(PI(3)K), and Rap-1 are directly involved in chemokine-mediated aLb2 lateral mobility in lymphocytes
(Constantin et al., 2000; Shimonaka et al., 2003). Rap-1 is a potent inside-out signal. Rap-1, PI(3)K, and
PKC are all reported to be involved in the activation of aLb2 (Katagiri et al., 2000).
Monoclonal antibodies recognizing the ligand-binding site of aLb2 (Petruzelli et al., 1995; Bazzoni
and Hemler, 1998) and aMb2 (Diamond and Springer, 1993) have been reported to bind preferentially to
activated integrins, to ligand-occupied forms of integrins, or induce activation themselves through
conformational changes in the extracellular domains to a high affinity for ligand. A 10,000-fold increase in
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affinity of aLb2 for its ligand, ICAM-1 could be obtained by creating an engineered conformational change
in the integrin I domain (Shimaoka et al., 2001; Lu et al., 2001b).
PROTEIN INTEGRIN REFERENCES
Tetraspanins
TM4SF b1 & b2 integrins,
aIIbb3
Porter and Hogg 1998;
Dedhar, 1999; Tarrant et al., 2003
Growth-factor receptors
EGF-R
PDGF-R-b
Insulin-R
ErbB2
VEGF-R-2
aVb3, a2b1
aVb3, aIIbb3
aVb3
a6b1, a6b4
aVb3, aVb5
Moro et al., 1998;Yu et al., 2000
Borges et al., 2000
Schneller et al., 1997; Maile et al., 2002
Falcioni et al., 1997; Gambaletta et al., 2000
Borges et al., 2000; Reynolds et al., 2002
GPI-linked receptors
uPAR (CD87)
FcgRIIIB (CD16B)
CD14
Thy-1 (CD90)
aL/M/Xb2, b1,3,5
aMb2
aMb2
aMb2, aXb2, aVb3
Kindzelskii et al., 1997; Carriero et al.,
1999; Yu et al., 2000; Simon et al., 2000
Petty and Todd, 1996
Petty and Todd, 1996
Wetzel et al., 2004; Choi et al., 2005;
Saalbach et al., 2005
Ig superfamily proteins
CD147 (EMMPRIN)
CD47 (IAP)
CD46 (MCP)
CD36
P2Y heptaspanin
Syndecan-4
a3b1, a6b1
a2b1, aVb3, aIIbb3
a3b1
a3b1, a6b1, aIIbb3
aVb3
a5b1
Berditchevski et al., 1997
Brown et al., 1990; Wang and Frazier, 1998
Lozahic et al., 2000
Dorahy et al., 1996; Thorne et al., 2000
Erb et al., 2001
Mostafavi-Pour et al., 2003
Transporters/Ion channels
16K V-ATPase
Kv1.3
GIRK
BAP31
ICln
b1 integrins
b1 integrins
b1 integrins
aMb2
aIIbb3
Skinner and Wildeman, 1999
Levite et al., 2001
McPhee et al., 1998; Ivanina et al., 2000
Zen et al., 2004
Larkin et al., 2004
Table 3. Integrins that interact with transmembrane proteins. TM4SF, transmembrane-4 superfamily; EGF-R,
epidermal growth factor receptor; PDGF-R, platelet-derived growth factor receptor; Thy1, thymus cell antigen 1;
EMMPRIN, extracellular matrix MMP inducer; IAP, integrin associated protein; MCP, membrane cofactor protein;
P2Y, purinergic receptor; Kv1.3, a voltage-gated potassium channel; GIRK, G protein-coupled inwardly rectifying
potassium channel; BAP31, B cell receptor-associated protein; ICln, a chloride channel regulatory protein.
Lateral redistribution and clustering of integrins (avidity regulation) may also have an impact on
cellular adhesion even though the affinity for ligand remains unchanged (Takada et al., 1997). For example,
treatment of leukocytes with phorbol esters induces clustering of b2-integrins by 10-fold (integrin avidity)
without altering affinity (Kucik et al., 1996), thus inducing b2-integrin-dependent leukocyte adhesion.
Phorbol esters directly activate PKC and bypass early signaling events which are transmitted by other
receptors (Wright and Silverstein, 1982). aLb2 clustering on the cell surface can also be induced by
interactions with cytoskeletal proteins (Stewart et al., 1998; van Kooyk et al., 1999). Treatment of
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lymphocytes with high concentrations of cytochalasin-D, which disrupts actin filaments, inhibited cell
adhesion to coated ICAM-1 induced by CD3 antibodies or phorbol esters (Stewart et al., 1998).
Transmission of signals into the cell by integrins can be generated after interactions with ligands or
counter-receptors on other cells or soluble ligands (the process is referred to as “outside-in” signaling). One
of the earliest events in b2 integrin signaling is the activation of both protein tyrosine kinases (PTKs),
including members of the focal adhesion kinase (FAK) family (p125FAK and Pyk2) and the Src-kinase family
(Fgr, Hck, Lyn, and Syk), which in turn can trigger downstream activation of multiple intracellular signaling
cascades, known to regulate cell morphology, cell growth and survival, adhesion, and migration. Various
cytoskeleton-associated proteins including paxillin, tensin, cortactin, and talin become tyrosine
phosphorylated in PMNs after ligand binding to b2 integrins. This strongly correlates with integrin b2-
mediated PMN spreading since such an effect was efficiently blocked by tyrosine kinase inhibitors (reviewed
in Berton and Lowell, 1999). Integrin engagement results in tyrosine phosphorylation of other cytoskeletal-
associated proteins, such as the cytoplasmic tyrosine kinase Fgr (Berton et al., 1994), the Syk tyrosine kinase
(Lin et al., 1995), phospholipase Cg2 (Hellberg et al., 1996), Vav (Zheng et al., 1996), the proto-oncogene
product Cbl (Ojaniemi et al., 1997), the mitogen-activated protein kinases ERK1/ERK2 (McGilvray et al.,
1997), p125FAK (Fernandez et al., 1997), and ZAP-70 (Soede et al., 1999). b2 integrin-dependent PMN
adhesion/spreading on fibrinogen correlates with Fgr or Lyn kinase activation (Berton et al., 1994; Yan et al.,
1995). These findings are also well-supported by data showing that leukocyte adhesion deficiency (LAD-I)
PMNs are unable to activate Fgr. In addition, both b2 integrin-deficient LAD-I cells (Berton et al., 1994) and
leukocytes expressing aLb2 integrin which lacks the I domain show impaired ”outside-in” signaling
(Leitinger and Hogg, 2000). Furthermore, double knockout mice for Hck and Fgr (hck-/- fgr-/-) showed
impaired PMN spreading on fibrinogen or ICAM-1 and failed to release large amounts of ROIs, even after
treatment with TNF or fMLP. Double mutant macrophages showed similar integrin-mediated cell spreading
defects (Lowell et al., 1996). Interestingly, collagen type I-binding to aLb2 integrin results in tyrosine
phosphorylation of both the a- and b-subunit of the integrin (Garnotel et al., 1995). However, not much is
known on the precise mechanisms by which these tyrosine kinases become enzymatically activated by
integrins in vivo.
Previous reports supported the idea that the aLb2 integrin prevails in inactive state (bent
conformation) when expressed on circulating lymphocytes (Carman and Springer, 2003; Salas et al., 2004)
and that it becomes activated by endothelium-anchored chemokines through specific G protein-coupled
receptors (GPCRs) which are present on the surface of leukocytes (Constantin et al., 2000). In this case,
integrins are known to regulate adhesion merely by clustering as lymphocytes move along the vessel wall.
Recently, Ronen Alon and colleagues proposed that chemokine-mediated aLb2 activation in T cells occurs
“locally”, with an immediate lymphocyte arrest and “bidirectionally”, which involves instantaneous inside-
out as well as outside-in conformational arrangements (extension of bent aLb2) of individual integrin
molecules (Shamri et al., 2005).
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MATRIX METALLOPROTEINASES
Matrix metalloproteinases (MMPs) are a family of structurally related and highly conserved zinc-
dependent endopeptidases collectively capable of degrading most components of the basement membrane
and ECM (Birkedal-Hansen et al., 1993; Nagase and Woessner, 1999). To date, there are at least 25 secreted
or membrane-bound known human MMPs (Sternlicht and Werb, 2001; Visse and Nagase, 2003). Data
generated from intensive studies on MMP activities in different cells and tissues, as well as studies from
knockout animals witness the importance of these enzymes in many normal physiological processes (e.g.
embryonic development, bone resorption, angiogenesis, and wound healing) and pathological processes
(rheumatoid arthritis, multiple sclerosis, periodontal disease, and tumor growth and metastasis) (Murphy and
Hembry, 1992; Nagase and Woessner, 1999; Egeblad and Werb, 2002; Hamano et al., 2003).
CLASSIFICATION
Most human MMPs can be divided according to their sequence homology, substrate specificity, and
cellular location (Shingleton et al., 1996) into several subclasses: collagenases, gelatinases, stromelysins,
matrilysins, membrane-type MMPs, and others (Murphy et al., 1991a; Nagase, 1994; Pendas et al., 1997)
(Figure 5).
STRUCTURAL FEATURES
The basic multidomain structure of MMPs comprises: (1) an amino-terminal domain; (2) a catalytic
domain; and (3) a carboxy-terminal domain. The amino-terminal domain contains a 17-29 amino acid signal
peptide, used as a signal for secretion of the proenzyme into the ER and eventually out of the cell, and a 77-
87 residue propeptide domain or pro-domain, that is responsible for keeping the enzyme inactive until
proteinase activity is needed. The pro-domain contains a highly conserved sequence, PRCG(V/N)PD in
which the cysteine residue interacts with the catalytic zinc atom in the active site, thus maintaining the
proMMP in its latent form. Disruption of the Cys-zinc covalent bond by a water-zinc interaction (called the
cysteine switch) and removal of the pro-domain may lead to a conformational change of the enzyme from
inactive to catalytically active form (van Wart and Birkedal-Hansen, 1990; Springman et al., 1990).
The catalytic domain contains about 160-180 residues, including calcium ion-binding sites and the
consensus zinc-binding HEBXHXBGBXHS motif (H for Histidine; E for glutamic acid; B for bulky
hydrophobic amino acid; G for Glycine; X for variable amino acid; S for Serine) (Murphy et al., 1991b;
Puente et al., 1996; Pendas et al., 1997). However, MMP-11 has threonine in place of serine (Stocker et al.,
1995) and MMP-17 has valine in place of serine (Puente et al., 1996). Together with the catalytic zinc ion,
this motif is essential for the proteolytic activity of MMPs. Additionally, there is a second, structural zinc
and at least one calcium ion located near the catalytic zinc, both important for stabilizing the MMP structure
(Borkakoti, 2000).
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The catalytic domain is linked to the hemopexin domain by a 5-50 residue proline-rich hinge region. In
comparison to MMP-7 (matrilysin-1), MMP-23, and MMP-26 (matrilysin-2), all other MMPs contain a ~200
residue and highly conserved C-terminal domain with a sequence similarity to a serum protein named
hemopexin. The hemopexin domain contains four repeats that are connected by a disulfide bridge at both
ends, thus allowing the domain to fold into a four-bladed propeller structure, with a calcium ion in the
middle of a central disc like structure (Morgunova et al., 1999). This domain is known to play a functional
role in protein in substrate binding, in interactions with the natural tissue inhibitors of metalloproteinases or
TIMPs (van Wart and Birkedal-Hansen, 1990; Sanchez-Lopez et al., 1993; Baragi et al., 1994), and in
forming MMP homodimers (Cha et al., 2002). Recently, the hemopexin domain of MMP-2 was shown to be
important for the activation of the protease (Morgunova et al., 1999; Overall et al., 1999). Additional
functional domains are present in some of the other MMP members. For example, three repeats of the
fibronectin-type II domain are present in the catalytic domain of gelatinases, MMP-2 and MMP-9 that are
capable of mediating enzyme binding to gelatin substrates (Murphy et al., 1994).
A transmembrane domain is known to be present in all MT-MMPs after an extension beyond the
hemopexin domain that localizes these proteases into the cell membrane. Unlike MT-MMPs, MMP-19
contains a further extension of the hemopexin domain but lacks the transmembrane-spanning region.
Figure 5. Domain structures of
human MMPs. Pre, signal
sequence; Pro, propeptide with
cysteine switch sequence; Zn,
zinc-ion binding site; CBD,
collagen/gelatin binding domain
or fibrinectin-type II repeats; F,
furin cleavage site; VN,
vitronectin-like insert; TM,
transmembrane domain; Cy,
cytoplasmic tail; SA, signal
anchor; GPI, GPI-anchoring
domain; CA, cysteine array; Ig,
Ig-like domain. Modified from
Westermarck and Kähäri, 1999.
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REGULATION OF MMPs
The expression, secretion, and activity of MMPs in normal tissues are subject to tight control. Most
MMPs are expressed at very low levels but their expression and activation can be rapidly induced at times of
tissue remodeling, such as during wound healing (Nagase and Woessner, 1999).
Transcriptional regulation
Transcription of MMPs is regulated by many factors, including cytokines, growth factors, oncogenic
cell transformation, physical stress, and cell-cell and cell-ECM interactions. Also, hormones, oncogenes, and
chemical agents like phorbol esters can upregulate (for example, IL-1, IL-6, TNF-a, EGF, PDGF, bFGF,
NGF, PMA) or downregulate (for example, IFN-g, TGF-b, retinoids, and glucocorticoids) the expression of
MMPs (Birkedal-Hansen et al., 1993; Borden and Heller, 1997; Westermarck and Kähäri, 1999; Nagase and
Woessner, 1999; Sternlinct and Werb, 2001). Unlike other MMPs, TGF-b does not suppress but slightly
induces transcription of MMP-2 (Brown et al., 1990; Overall et al., 1991). Many of these inducers of MMP
expression are known to act at the level of transcriptional activation of the gene. The promoters of many
MMP genes (such as MMP-1, -3, -7, -10, -12, -13, and -19) include an activator protein-1 (AP-1) consensus
element which is located approximately at position -70 and one or two copies of the polyomavirus enhancer
A-binding protein-3 (PEA-3) element at position between -140 and -200. AP-1 and PEA-3 sites interact with
the Fos and Jun families and the Ets family of transcription factors, respectively (Westermarck and Kähäri,
1999). Several reports have shown that these cis-elements are important for the regulation of MMP gene
expression at the basal gene-expression level and in response to extracellular stimuli like growth factors,
cytokines, and phorbol esters (Angel et al., 1987; Westermarck and Kähäri, 1999). For example, the MAPK
pathway, which comprises ERK1/2, JNK, and p38 proteins can induce the expression of AP-1 transcription
factors, which is considered by many to be the major activators of MMP-1, -3, -9, and -13 expresion
(Westermark and Kähäri, 1999). However, several reports show differences between promoter regions of
MMP-2 and other MMPs (Matrisian, 1994). MMP-2 gene is distinguished by the lack of the AP-1 and PEA-
3 regulatory elements in the promoter region, which explains the lack of transcriptional regulation of MMP-2
expression. The MMP-2 promoter also lacks the TATA site which is important in regulating the transcription
of most promoters, as well as the upstream TGF-? inhibitory element (TIE) and AP-1 element (Matrisian,
1994; Huhtala et al., 1990; Tryggvason et al., 1990). The latter is shown to interact with AP-1 transcription
complexes. Also, single-nucleotide polymorphisms have been identified within several MMP gene
promoters, which affect the rate of transcription, and influence the development and progression of several
diseases, including cancer (Ye, 2000). Finally, the expression of many MMPs can be upregulated by ligand
and/or antibody-binding to integrins (Werb et al., 1989; Dumin et al., 2001). For example, aLb2-, aMb2- and
a3b1-integrin ligation promotes the expression of MMP-9. Accordingly, inhibition of these integrins by
antisense oligonucleotides leads to reduced MMP-9 expression (Aoudjit et al., 1998; DiPersio et al., 2000).
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Zymogen activation
Interaction between the unpaired cysteine residue which is located in the prodomain and the
conserved zinc atom at the active site is thought to be responsible in maintaining the latency of MMPs
(Springman et al., 1990; van Wart and Birkedal-Hansen, 1990). Disruption of the covalent bond which
associates the zinc atom with the cysteine residue and coordination with H2O can lead to the cleavage of the
prodomain and further activation of proMMPs (Nagase and Woessner, 1999; Curran and Murray, 2000).
Most MMPs are known to be secreted as inactive zymogens and activated extracellularly by many different
mechanisms (Will et al., 1996; Cao et al., 1996; Kinoshita et al., 1998; Mazzieri et al., 1997; Wang et al.,
2000). Most proMMPs are also known to be activated in the pericellular space by serum or tissue
proteinases, bacterial proteinases, and other MMPs. Proteinases, such as trypsin, plasmin, kallikrein,
chymase and mast cell chymase, are capable of activating proMMPs in vitro. ProMMPs can also be activated
by various non-proteolytic agents, including mercurial compounds (aminophenyl mercuric acetate or
APMA), SH-reactive agents, chaotropic agents, reactive oxygen, detergents, and heat treatment (Springman
et al., 1990; Saarialho-kere et al., 1992; Murphy and Knäuper, 1997; Nagase and Woessner, 1999). In case of
MMP-2, -8, and -9, activation can occur when exposed to acidic pH followed by neutralization (Davis,
1991).
In vivo proMMP activation is found to localize in both to the intracellular and extracellular milieus,
and on the cell surface (Nagase and Woessner, 1999; Visse and Nagase, 2003). MMP-11 (stromelysin-3),
MMP-21, -23, -28, and MT-MMPs are activated intracellularly by Golgi-associated, furin-like serine
proteases (Pei and Weiss, 1996; Kang et al., 2002; Visse and Nagase, 2003). It has been reported that in the
case of MMP-23, a single cleavage is enough to induce both activation and release of MMP-23 from the cell
surface (Pei et al., 2000).
MMP-2 is resistant to proteolytic activation by serine proteases and other endopeptidases because it
lacks a basic amino acid motif, present in most other MMPs (van Wart and Birkedal-Hansen, 1990; Curran et
al., 2000; Vihinen and Kähäri, 2002). However, MMP-2 activity is highly regulated by MT-MMPs,
membrane localized MMPs which are important activators of proMMPs in the pericellular space
(Brinckerhoff et al., 2000). Firstly, MT-MMPs, such as MT1-MMP and MT3-MMP form cell-surface
complexes with tissue inhibitors of MMPs, TIMP-2 and TIMP-2 or TIMP-3, respectively, through their C-
terminal tail (Strongin et al., 1995; Zhao et al., 2004). Secondly, TIMP-free MT-MMP can activate
proMMP-2 (Zucker et al., 1998; Wang et al., 2000; Overall et al., 2000). In many cases, MMP activation is
achieved by autocatalytical activation, the cell-surface associated urokinase-type plasminogen activator
(uPA)/plasmin-dependent activation system, and by other proteinases (Carmeliet et al., 1997; Mazzieri et al.,
1997).
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Inhibition of enzymatic activity
Specific inhibition of the activity of MMPs can be achieved in the pericellular milieu by the non-
specific, circulating protease inhibitors, a2-macroglobulin (a2M), serpins, and by the specific TIMPs. a2M is
a homotetramer, made of two pairs of non-covalently associated dimers, capable of inhibiting MMP activity
in the synovial fluid, serum, and other body fluids. It can also inhibit the activity of several other enzymes,
including serine-, cysteine-, and aspartate proteinases. Serpins, including a1-antitrypsin (a1-proteinase
inhibitor) and plasminogen activator inhibitor (PAI)-1 and -2, are glycoproteins of 50-100 kDa, involved in
regulating the proteolytic activity of MMPs in various tissues (Saarialho-Kere et al, 1992; Birkedal-Hansen
et al., 1993).
TIMPs are known to be the key endogenous regulators of MMP activities in tissues. Four known
members of the TIMP family (TIMPs-1, -2, -3, and -4) have been identified to date, all anchored in the ECM
or secreted extracellularly (for reviews see Gomez et al., 1997; Westermarck and Kähäri, 1999; Brew et al.,
2000).  In spite of the fact that all TIMPs share very similar structural features and inhibitory capabilities
against almost all MMPs, they exhibit differences in tissue distribution, in their ability to interact with the
latent forms of MMPs and to inhibit their activity, in solubility, and in their gene regulation patterns (Nagase
and Woessner, 1999; McCawley and Matrisian, 2000; Sternlinct and Werb, 2001). They contain 12
conserved cysteine residues required for building up six disulfide bonds, which keep the two domains in a
rigid conformation (Douglas et al., 1997; Gomez et al., 1997). TIMPs form non-covalent 1:1 stoichiometric
complexes with the zinc-binding catalytic site of active MMPs, thus inhibiting proteolytic activity (Gomis-
Rüth et al., 1997). The N-terminal domain of TIMPs contains a consensus sequence VIRAK which is
required for MMP inhibition, whereas the C-terminal domain seems to affect their specificity (Murphy et al.,
1991b; DeClerck et al., 1993; Goldberg et al., 1992; Ogata et al., 1995; Bigg et al., 1997). TIMPs are capable
of inhibiting not only active MMPs but also can prevent autocatalytic activation of several MMPs (DeClerck
et al., 1991; Strongin et al., 1993) by forming complexes with proenzymes.
In vitro TIMPs can inhibit the activation of almost all MMPs. For instance, TIMP-1 and TIMP-2 can
preferentially inhibit MMP activation by forming a complex with proMMP-9 and proMMP-2, respectively,
via the hemopexin domain. TIMP-1 blocks the activity of most MMPs, with the exception of MT1- and
MT3-MMPs. Finally, TIMP-1 inhibits cleavage and secretion of heparin-binding EGF-like growth factor and
its receptor HER-2 from the surface of breast cancer cells (Dethlefsen et al., 1998; Codony-Servat et al.,
1999). Whereas for TIMP-1 to be expressed in culture requires growth factors, cytokines, and phorbol esters,
the expression of TIMP-2 is constitutive (Gomez et al., 1997). TIMP-2 is expressed in culture by a variety of
cells in a constitutive manner and also inhibits the activity of most MMPs (Strongin et al., 1993), but not
MMP-9. This particular MMP inhibitor is capable of blocking the shedding of TNF-a receptors I and II
(TNF-aRI and II). Unlike the other TIMPs, which are secreted in soluble forms in tissues and body fluids,
TIMP-3 is insoluble and found associated with the ECM (Leco et al., 1994). TIMP-3 can inhibit the shedding
of pro-TNF-a, L-selectin, and IL-6 receptor from the surface of human peripheral leukocytes and myeloma
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cells (Borland et al., 1999). TIMP-4 is mainly expressed in the adult human heart (Greene et al., 1996) and
can also form a complex with proMMP-2 (Goldberg et al., 1989).
Finally, several proteinases from the ADAM family can also be inhibited by TIMPs due to their
structural similarities with MMPs in the active site. For example, both TIMP-1 and TIMP-3 can inhibit
ADAM10 and ADAMTS4 (aggrecanase-1) (Amour et al., 2000; Kashiwagi et al., 2001). TIMP-3 alone also
inhibits ADAM17 (TNF-a convertase) and ADAMTS5 (aggrecanase-2) (Kashiwagi et al., 2001).
ROLE OF INTEGRINS AND MMPs IN LEUKOCYTE MIGRATION
REGULATION OF CELL ADHESION AND MIGRATION
Leukocyte migration is a complex process, controlled by a wide spectrum of adhesion molecules that
are expressed on both leukocytes and endothelial cells, and by the presence of chemotactic molecules. These
molecules, as well as growth factors, are responsible for the establishement of a polarised cell migration and
there is enough evidence to prove that signaling from both phospholipids and proteins from the Rho family
of small GTPases are also involved in directed cell motility (Rickert et al., 2000). Migration of leukocytes is
essential for immune responses, tissue repair, and embryonic development. When cell migration is not
regulated, this may lead to cancer invasion and metastasis.
Integrins have attracted much attention by their strong contribution to the anchorage of cells to the
ECM and migration across it. During spreading of cells on the ECM, integrins form large aggregates with
their other associated proteins at sites where the plasma membrane and the matrix remain in close contact.
These are called cell-matrix adhesion sites. Engagement of integrins by ECM proteins induces binding of
filamentous (F)-actin to the integrin cytoplasmic domains, mediated by several adaptor proteins of the
cytoskeleton (Geiger et al., 2001). In addition, different structures described by small adhesions that are
present in membrane protrusions, elongated adhesions made of an assembly of fibronectin molecules, and
large adhesions formed by F-actin stress fibers, occur in spreading cells and represent the “focal complexes”,
“fibrillar adhesions”, and “large adhesions”, respectively (Zamir and Geiger, 2001). In fibroblasts, structures
where integrins and signaling molecules are associated intracellularly are described as “focal adhesions”.
Many integrins bind to fibronectin via the same integrin-binding motif, Arg-Gly-Asp (RGD), also present in
many other ECM proteins. For example, a4b1 and a5b1 integrins, both expressed in leukocytes, have been
shown to bind to fibronectin but via a different mechanism (Weber et al., 1996). a4b1, a5b1, aLb2, and aMb2
integrins are involved in the regulation of chemokine-induced adhesion and spreading of leukocytes (Peled et
al., 2000; Voermans et al., 2000). Mice with a deletion of the a4-subunit gene showed decrease in T-cell
homing to Peyer patches (Arrojo et al., 1996). Antibodies against the same subunit blocked SDF-1-induced
transendothelial migration of CD34+ cells (Peled et al., 2000). a2b1 integrin also plays a prominant role in
leukocyte migration and inhibition of this integrin prevented neutrophil migration by 70 % (Werr et al.,
36
1998; 2000b).  Data from mice that lack b2 integrins showed impaired neutrophil infiltration to inflammatory
sites (Borjesson et al., 2003). Moreover, antibody cross-linking of b2 integrins has been shown to upregulate
b1-integrin expression (Werr et al., 2000a). Similar effect on b1-integrin expression was detected in
leukocytes after transendothelial migration (Kubes et al., 1995; Werr et al., 1998; 2000b). Taken together,
adhesion and migration of neutrophils is strongly associated with b1 and b2 integrin expression and
activation.
During migration, signaling through the chemokine receptors (inside-out) triggers changes in the
distribution of filamentous F-actin in leukocytes, which undergo morphological changes, characterized by a
switch from a spherical to a polarized shape (Howard and Oresajo, 1985). During cell polarization, leukocyte
integrins, chemoattractant receptors and other adhesion molecules, cytoskeletal proteins and intracellular
regulatory molecules change their cellular localization. Polarization of leukocytes occurs not only during cell
attachment to the vascular endothelium mediated by integrins, but also during antigen presentation and
target-cell recognition (reviewed in Sanchez-Madrid and Del Pozo, 1999). A polarized morphology of
leukocytes was first described to be similar to that of a migrating amoebae, with a leading edge at the front
and a uropod at the rear of a migrating cell (Wilkinson, 1986). T cells recognize and bind to APCs through
their leading edge (Kupfer and Singer, 1989). Changes in T cells, such as cell surface protein clustering,
cytokine secretion, and cytoskeletal reorganization triggered after contact with APCs have been extensively
studied (Kupfer and Singer, 1989).
A number of receptors are concentrated at the leading edge, including aVb3, uPAR, and fMLP-R in
neutrophils; CCR2, CCR5, and FAK in T cells; and CXCR4 in B cells, which are able to sense chemotactic
gradients, thus guiding leukocytes to migrate in a polarized manner. Antibody-specific cross-linking to L-
selectin induced the translocation of intracellular vesicle-stored CXCR4 to specific sites on the surface of T
cells, called lipid rafts (Sitrin et al., 2004). At the uropod, several reports show localization of ICAMs, L-
selectin, aMb2, PSGL-1, FcgR-IIIb, CD2, CD43, and CD44 (reviewed in Sanchez-Madrid and del Pozo,
1999; Webb et al., 2002), which play a pivotal role in cell adhesion, thus facilitating cell migration.
However, the a5b1 integrin can be translocated via endosomes from the uropod to the leading edge of
neutrophils (Pierini et al., 2000). Release of the uropod triggers cell migration. Some of these receptors when
bound to the substratum, become linked to the actin cytoskeleton during cell migration. Interactions between
the cytoskeleton and the cell surface receptors are required for the formation of membrane protrusions, such
as lamellipodia (broad, sheet-like structures) and filopodia (thin cylindrical needle-like projections), both
structures located at the leading edge (Nobes and Hall, 1995). The ERM proteins (ezrin, radixin, and moesin)
are localized at cell-surface protrusions and form a link between the actin cytoskeleton and the cytoplasmic
tails of the membrane receptors. It has been suggested that the association of fMLP receptor with talin
regulates actin polymerization in neutrophils (Jesaitis et al., 1993).
Changes in the actin cytoskeleton in response to extracellular stimuli are mainly regulated by the
Rho family of small GTPases, such as Rac, Cdc42, and RhoA (Nobes and Hall, 1995). Rac1 mediates
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lamellipodia formation (Ridley et al., 1992), Cdc42 promotes filopodia formation (Kozma et al., 1995), and
RhoA controls focal adhesion formation and actomyocin-mediated contraction in fibroblasts (Ridley and
Hall, 1992). Myocin-induced contraction of the actin network can pull the cell to migrate, suggesting that
RhoA is implicated in the uropod retraction. Rho is known to be involved in aLb2/ICAM-1-dependent
leukocyte aggregation and adhesion through integrins (Laudanna et al., 1996; Sanchez-Madrid and del Pozo,
1999). The actin network is assembled at the leading edge which allows continuous movement of the
leukocyte while it disassembles at the rear (Mitchison and Cramer, 1996). Myosin, a motor protein, seems to
play an important role in migration of leukocytes and other cells by gathering several adhesion receptors,
including integrins towards the uropod, as suggested by studies performed on myosin-deficient amoebae
(Wessels et al., 1988). Second messengers (calcium and cAMP) and protein (PKA, PKC, and FAK) or lipid
(PI3K) kinases also play important role in cell migration. In migrating leukocytes, calcium is involved in the
regulation of the myosin (located at the uropod)-induced cell contraction, which is manifested by the high
Ca2+ levels observed at the cell rear. Adhesion receptors attached to the substrate move backwards as the cell
migrates, while at the same time, renewal of these receptors such as integrins occurs at the leading edge.
Altogether, a combination of high calcium and cAMP concentrations, and low Rho GTPases activity can
lead to disruption of actin filaments, as well as induction of cell detachment via myosin-dependent
contraction and formation of the uropod, whereas low levels of these second messengers and Rho GTPases
and high phosphoinositide levels can promote cell adhesions and formation of lamellipodia and filopodia at
the leading edge via increase in integrin activation and actin filament assembly (Janmey, 1994). During
transmigration, RhoA and its effector, p160ROCK, are both required for retraction of the leukocyte tail.
Inhibition of RhoA led to the translocation of b2 integrins from front to the rear of migrating leukocytes
(Worthylake et al., 2001), as well as failure to retract the uropod. Thus, coordination of these molecules at
specific places in the cell can determine the assembly or desessembly of the actin cytoskeleton and the
localization of membrane protrusions and retractions. Finally, several MMPs, including MT1-MMP and
MMP-2 were found to colocalize at membrane protrusions. Interaction of MMPs with their natural
inhibitors, TIMPs at these sites might be the key mechanism for the regulation of cell surface-MMP
activation and eventually, the control of the invasive phenotype of cells (reviewed in Chen and Wang, 1999).
MT1-MMP can promote signal transduction and regulate gene expression. Indeed, transfection of cells with
the MT1-MMP gene induced the activation of the extracellular signal-regulated protein kinase (ERK)
cascade and Rac 1, leading to increased cell migration (Takino et al., 2004; Cao et al., 2004). MT1-MMP
mediated-cleavage of the integrin aV subunit of the aVb3 integrin resulted in focal adhesion kinase (FAK)
phosphorylation and cell migration. Interestingly, shedding of CD44 (Kajita et al., 2001) and LRP (Rozanov
et al., 2004) ectodomains by MT1-MMP promotes the release and translocation of the cytoplasmic fragment
from the cell surface into the nucleus for transcriptional activation (Nakamura et al., 2004).
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CELL SURFACE ASSOCIATION OF MMPs AND OTHER PROTEASES
MMPs are secreted as zymogens from inside the cell to the cell surface and into the extracellular
environment where they are able to degrade both ECM and non-ECM proteins. It remains unclear how these
enzymes make it to the correct location at the cell surface and how the proteolytic activity is controlled at the
pericellular space. However, it has been suggested that MMP-binding to cell surface proteins can have an
effect on intracellular signaling, can facilitate proenzyme localization and activation, mediate cell motility by
disruption of cell contacts with the ECM and promote internalization of the enzyme. For example, integrins
are shown to act as receptors for several proteases, including MMPs. Such interactions have been detected in
caveolae, in invadopodia, and at the leading edge of migrating cells, where directed proteolytic activity is
needed. The first interaction between an integrin (aVb3) and a MMP (MMP-2) was identified on the surface
of melanoma cells and angiogenic blood vessels (Table 5). This complex was shown to be involved in tumor
growth and angiogenesis in vivo (Brooks et al., 1998). Immunofluorescence and confocal microscopic
studies showed the colocalization of MT1-MMP and TIMP-2 with caveolin-1 in the same membrane
microdomains with MMP-2 and aVb3 integrin (Puyraimond et al., 2001), termed caveolae. Caveolae are
membrane invaginations enriched in cholesterol and glycolipids and serve as sites for clustering of various
integrins and proteases (Smart et al., 1999). They are involved in the transport of lipids, in signal
transduction pathways and in non-clathrin-mediated endocytosis (reviewed in van Deurs et al., 2003). MT1-
MMP was shown to activate aVb3 through proteolytic cleavage, suggesting that coordinated expression and
localization of these molecules may be important for cancer cell invasion and metastasis. Furthermore, there
is evidence that the aVb3 integrin has modulatory properties on MMP-2 activity by binding to its C-terminal
domain (Brooks et al., 1996; Brooks et al., 1998). Inhibition of the aVb3/MMP-2 complex formation by
either the MMP-2 C-terminal domain (Pfeifer et al., 2000) or a small molecule inhibitor, TSRI265 (Silletti et
al., 2001) dramatically suppressed angiogenesis in vivo, demonstrating that this interaction is essential for
endothelial cell proliferation and migration. The TSRI265 molecule neither blocked MMP-2 protease activity
nor aVb3-mediated cell adhesion. Since then, several other important protease associations with integrins
have been reported (Table 5), suggesting that pericellular proteolysis may be activated and targeted by
integrins and other cell surface receptors. Another gelatinase, proMMP-9 has been detected on the surface of
many cell types, including leukocytes, endothelial cells, keratinocytes, and in a variety of malignant cells as
a proenzyme and often free of TIMP-1 (reviewed in Seiki et al., 2003). A complex between proMMP-9 and
TIMP-1 was detected in the culture media of breast epithelial MCF10A cells but not on the cell surface after
treatment with phorbol esters, suggesting that cell surface-bound proMMP-9 may prevent its inhibitor from
binding to it (Toth et al., 1997).
In leukocytes, uPA could bind to its receptor, uPAR, and to aMb2 simultaneously, forming a
trimolecular complex where aMb2 could serve as a signaling receptor (Pluskota et al., 2003). This interaction
is likely to be mediated by both the kringle and proteolytic domains for uPA and the I-domain for aMb2. A
peptide sequence within the aM subunit and outside the I domain was shown to bind uPAR (Simon et al.,
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2000). This complex plays an essential role in the migration of inflammatory cells and vascular homeostasis.
The uPA/uPAR complex was also found associated with the a5b1 integrin and capable of promoting adhesion
and migration of Chinese hamster ovary cells as well as intracellular signal transduction through the integrin.
The uPA/uPAR and uPAR/b1 integrin complexes were also reported to be present in caveolae of
chondrocytes (Schwab et al., 2001; Tarui et al., 2003). Recently, proMMP-9 was found to be associated with
ICAM-1 (Fiore et al., 2002) and DNA repair protein Ku (Monferran et al., 2004) on the surface of leukemic
cells. ICAM-1 cleavage by MMP-9 resulted in tumor cell resistance to natural killer cell-mediated
cytotoxicity.
Soluble
proteases
Associated
proteins
Cell-surface
expression
References
MMPs
MMP-1 a1b1
a2b1
EMMPRIN
myocytes
keratinocytes
lung carcinoma
Stricker et al., 2001
Dumin et al., 2001
Guo et al., 2000
MMP-2
PAR1
aVb3
LRP
collagen chains
TSP-2
TIMP-2
caveolin-1
Hsp90a
breast carcinoma
melanoma, endothelial
fibroblasts
fibroblasts
fibroblasts
malignant cells
endothelial
fibrosarcoma
Boire et al., 2005
Brooks et al., 1996; 1998
Yang et al., 2001
Steffensen et al., 1998
Yang et al., 2001
Olson et al., 1997
Puyraimond et al., 2001
Eustace et al., 2004
MMP-3
MMP-7
MT1-MMP
BS
osteopontin
CD44HSPG
TM4SF
fibrosarcoma
       -
       -
epithelial
       -
Strongin et al., 1995
Fedarko et al., 2004
Fedarko et al., 2004
Yu & Woessner, 2000
Maecker et al., 1997
MMP-9
CD151
collagen chains
RECK
CD44
ICAM-1
LRP
Ku protein
TIMP-1
TSP-1
aL/Mb2
a5b1
a3b1
aVb5
rectal carcinoma
epithelial/fibrosarcoma
fibrosarcoma
melanoma
leukemias
fibroblasts
macrophages/leukemia
fibroblasts
malignant cells
neutrophils/leukemias
epithelial
mammary carcinoma
fibrosarcoma
Shiomi et al., 2005
Okada et al., 1992
Takahashi et al., 1998
Yu & Stamenkovic, 1999
Fiore et al., 2002
Hahn-Dantona et al., 2001
Monferran et al., 2004
O’Connell et al., 1994
Rodriguez-Manzaneque, 2001
Stefanidakis et al., 2004
Wang et al., 2003
Morini et al., 2000
Bjorklund et al., 2004
MT1-MMP
DMP-1
aVb3
b1 subunit
CD44
TIMP-2
collagen type I
RECK
       -
endothelial
endothelial
fibrosarcoma
breast carcinoma
gingival fibroblasts
fibrosarcoma
Fedarko et al., 2004
Galvez et al., 2002
Galvez et al., 2002
Mori et al., 2002
Imai et al., 1996
Tam et al., 2002
Oh et al., 2001
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Serine
proteases
uPA uPAR, which
in turn interacts
with : aM/Xb2
: aVb3
: aVb5
: a3b1
malignant
neutrophils
fibrosarcoma
mammary carcinoma
mammary carcinoma
Ellis et al., 1999
Xue et al., 1994
Xue et al., 1997
Carriero et al., 1999
Wei et al., 2001
elastase aMb2 neutrophils Cai and Wright, 1996
seprase uPAR
a3b1
melanoma
melanoma
Artym et al., 2002
Monsky et al., 1994
Dipeptidyl
peptidase IV
a3b1 fibroblasts Ghersi et al., 2002
cathepsin G FPR
HIV-1 gp120
membrane Gp
leukemias
leukemias
platelets/neutrophils
Sun et al., 2004
Avril et al., 1994
Molino et al., 1993
proteinase 3 aMb2 neutrophils David et al., 2003
plasmin Annexin II kidney cells MacLeod et al., 2003
Cysteine
proteases
Cathepsin B annexin II
a2-M
tumors
bone metastases
Mai et al., 2000
Arkona & Wiederander, 1996
ADAMs
ADAM-2 a6b1 Oocytes                             Chen and Sampson, 1999
ADAM-7 a4b1
a9b1
a4b7
T cell leukemia
T cell leukemia
T cell leukemia
Bridges et al., 2005
Bridges et al., 2005
Bridges et al., 2005
ADAM-9 a6b1
a9b1
aVb5
fibroblasts
oocytes
Myeloma
Nath et al., 2000
Eto et al., 2002
Zhou et al., 2001
ADAM-12 a9b1 haematopoietic Zhang et al., 1998
ADAM-15 aVb3
a5b1
a9b1
haematopoietic
haematopoietic
oocytes
Nath et al., 1999
Nath et al., 1999
Eto et al., 2000
ADAM-17 a5b1 epithelial Bax et al., 2004
ADAM-23 aVb3 neuroblastoma Cal et al., 2000
ADAM-28 a4b1
a9b1
a4b7
lymphocytes
T cell leukemia
T cell leukemia
Bridges et al., 2002
Bridges et al., 2005
Bridges et al., 2005
ADAM-33 a9b1 T cell leukemia Bridges et al., 2005
Table 5. Cell-surface MMP-associated proteins. Many of the functions and binding mechanisms of these comlexes
have not been elucidated yet. ADAM, a disintegrin and metalloproteinase; a2-M, a2-macroglobulin; BS, bone
sialoprotein; DMP-1, dentin matrix protein-1; FPR, formyl peptide receptor; Gp, membrane glycoproteins; Hsp, heat
shock protein; HSPG, heparan sulfate proteoglycans; PAR1, protease-activated receptor 1; RECK reversion-inducing
cysteine-rich protein with kazal motifs.
Also, a chaperone heat shock protein90 (Hsp90) was found to interact with MMP-2 on the cell surface of
fibrosarcoma cells, thus promoting MMP-2 activation, which is critical for tumour invasiveness (Eustace et
al., 2004). The binding mechanism of most of these interactions has not been yet elucidated.
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Several cell surface hyaluronan receptor CD44 isoforms, RECK, TSP-1, LRP, and cell surface
collagen IV chains also serve as MMP-9-docking molecules. The CD44/MMP-9 complex was found to be
associated with invasiveness of mouse mammary carcinoma and human melanoma cells in vivo (Yu and
Stamenkovic, 1999), suggesting that CD44 helps to localize MMP-9 activity to the cell surface. Disruption
of the CD44/MMP-9 complex by a soluble CD44 molecule resulted in the loss of tumor invasiveness and
survival mediated via latent transforming growth factor-beta (TGF-b) activation. The GPI-linked proteins
RECK and TSP-1 were not only identified as cell surface receptors for MMP -9 but also were found to block
their enzymatic activity (Oh et al., 2001; Rodriguez-Manzaneque et al., 2001). Recombinant purified RECK
was also known to inhibit the activity of MT1-MMP in vitro (Oh et al., 2001). When the expression of
RECK was restored in cells which lack the endogenous protein, the invasive, metastatic, and angiogenic
phenotypes of these tumor cells were strongly suppressed (Takahashi et al., 1998; Oh et al., 2001; Liu et al.,
2003). TSP-2 is capable of regulating the proteolytic activity of MMP-2, forming a tight complex that
induces scavanger receptor-mediated endocytosis and clearance (Yang et al., 2001). Interaction of MMPs
with the cell surface may not only be needed for proenzyme activation and targeting at specific sites for
degradation of cell-surface substrates, but could also promote intracellular degradation via receptor-mediated
endocytosis (RME). For example, the LDL receptor-related protein, LRP is capable of inducing RME of
MMP-2, -9, and -13, three MMPs known to have a key role in promoting tumour invasion and metastasis
(Emonard et al., 2004; reviewed in Emonard et al., 2005). MT1-MMP can regulate such interactions as it has
been described to proteolytically process CD44 (Kajita et al., 2001) and more recently, LRP (Rozanov et al.,
2004), a possible mechanism utilized by tumor cells to maintain an invasive phenotype. Regulation of the
cell surface activity of proteolytic enzymes that are involved in cancer progression, including MMP-2, -9, -
13, tPA, and uPA by endocytosis has led to suppression of tumour cell invasion (Czekay et al., 2001). Both
MMP-2 and -9 were found bound to the surface of various cell lines via a surface-associated a2(IV) chain of
collagen type IV (Olson et al., 1998; Toth et al., 1999). ProMMP-9 bound to a2(IV) collagen chain with a
high affinity and this interaction is thought to be mediated by the collagen-binding domain as TIMP-1,
known to recognize the hemopexin domain, had no effect on this interaction. However, the hemopexin
domain of proMMP-9 was recently shown to be important for binding gelatin (Roeb et al., 2002). MMP-8,
MMP-19, and other proteases also localize to the cell surface by a mechanism that has not yet been
determined.
A Disintegrin and a Metalloproteinase (ADAMs) and ADAM with a thrombospondin motif
(ADAMTS) are large family of proteins capable of interacting with integrins and involved in processes such
as angiogenesis, fertilization, myogenesis, neurogenesis, and inflammation. Unlike the transmembrane
proteins ADAMs, ADAMTS proteins are soluble ECM proteases consisting of a prodomain, metalloprotease
and disintegrin domains, but devoid of ADAMs’ cystein-rich, EGF-like, transmembrane and cytoplasmic
domains (reviewed in Primakoff and Myles, 2000). ADAM2 or fertilin b was one of the first disintegrin
identified and found to interact with a6b1 integrin (Chen et al., 1999). Based on knockout mice studies,
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ADAM2 was found to have an important role in mediating sperm-egg adhesion (Cho et al., 1998). To date,
several other ADAM-integrin interactions have been identified: ADAM9 with avb5 and a6b1, ADAM12 and
ADAM15 with a9b1, ADAM15 and ADAM23 with avb3, and ADAM15 with a5b1 (reviewed in Evans,
2001) (Table 5).
ROLE OF INTEGRINS AND GELATINASES IN CANCER PROGRESSION
Early events in tumor progression are characterized by increases in cell proliferation, insensitivity to
growth-inhibitory signals, reduced ability for differentiation, as well as the ability to escape from apoptosis
and immune surveillance (Hanahan and Weinberg, 2000). Proteinases that degrade components of the ECM
and are capable of processing nonmatrix substrates (e.g. growth factors and its receptors, chemokines,
adhesion molecules, and apoptotic mediators) have long been considered to be important at all stages of
tumorigenesis (Coussens and Werb, 2001). The combined participation of integrins and MMPs is required
for invasion of tumor cells into surrounding connective tissues, intravasation and extravasation from blood
vessels, and metastasis to distant organs (reviewed in McCawley and Matrisian, 2000). Indeed, studies on
TIMPs have shown that overexpression or administration of these inhibitors as recombinant proteins
inhibited experimental invasion and metastasis (Alvarez et al., 1990; Khokha, 1994; Codony-Servat et al.,
1999; Turpeenniemi-Hujanen, 2005). In most cases, the stage of tumor progression correlates with the
expression levels of gelatinases as the invasive and metastatic potential of tumor cells is strongly affected by
changes in gelatinase expression in animal models. MMP levels can appear elevated even in the early stages
of tumor progression (Stetler-Stevenson, 1996). Expression of MMP-2 and MMP-9 was found to be strongly
upregulated in cancers of lung, colon, breast, skin, and prostate which correlated with increased tumor
invasiveness and metastasis (reviewed in Egeblad and Werb, 2002). Inhibition of MMP-9 expression in a
model of experimental metastasis reduced the number of colonies formed in the lung of mice (Hua and
Muschel, 1996).  Further evidence supporting this hypothesis came from studies on MMP-2 and -9 null mice.
These mice developed fewer tumors than the wild-type (reviewed in Sternlinct and Werb, 2001).
INTEGRINS AND GELATINASES IN TUMOR ANGIOGENESIS AND GROWTH
Angiogenesis, the formation of new blood vessels from pre-existing ones is essential for tumor
growth (Hanahan and Folkman, 1996). Growth and metastasis of many cancers require the incorporation of
vascular and lymphatic endothelial cells from pre-existing neighbouring vessels (Folkman, 1995; He et al.,
2004). Among MMPs, gelatinases are important positive regulators of angiogenesis as both their natural and
synthetic MMP inhibitors have the ability to decrease vessel sprouting into tumors in several experimental
models in vitro and in vivo (Schnaper et al., 1993; Itoh et al., 1998; Vu et al., 1998; Gatto et al., 1999; Oh et
al., 2001; Li et al., 2001). The role of gelatinases in tumor angiogenesis is also supported by the tumor-
specific efficacy of MMP inhibitors in several transgenic models. For example, MMP-9 has been shown to
be important for angiogenesis in the K14-HPV16 skin (Coussens et al., 2000) and RIP-TAg pancreatic islet
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(Bergers et al., 2000) tumor progression models. The authors demonstrated that MMP-9 regulates tumor
angiogenesis by releasing the pro-angiogenic factor VEGF from ECM and makes its available for binding to
its receptors. Mobilization of VEGF was inhibited by TSP-1, an MMP-9 inhibitor and potential endogenous
suppressor of capillary morphogenesis in vivo, which resulted in decrease of tumor growth by an
antiangiogenic mechanism (Rodriguez-Manzaneque et al., 2001). Interestingly, MMP-2 did not seem to be
required for angiogenesis in the RIP-TAg model, but strongly reduced tumor development. However,
downregulation of MMP-2 expression decreased angiogenesis in a chicken chorioallantoic membrane model
(Fang et al., 2000). Studies on MMP-2- (Itoh et al, 1998) and MMP-9- (Vu et al., 1998) null mice show
impaired tumor angiogenesis and growth compared with the wild-type. Cleavage of type IV collagen
triggered by MMP-2 exposes a cryptic, avb3 integrin binding site within the collagen. Indeed, an antibody
recognizing the site strongly inhibited angiogenesis in vitro and tumor growth in vivo (Xu et al., 2001). In
addition, epitope exposure correlated with proMMP-2 activation and increase of avb3 binding, suggesting
that interaction between the cryptic site of collagen IV and avb3 could promote MT1-MMP/MMP-2
activation and eventually, increased tumor growth and invasion. In addition, MT1-MMP (Zhou et al., 2000;
Galvez et al., 2001) and cathepsins (Joyce et al., 2004) have been able to trigger the angiogenic switch,
suggesting the existance of important positive regulators other than MMP-9.
Gelatinase-induced cleavage of matrix components releases fragments with anti-angiogenic activity.
For example, MMP-2 and MMP-9 cleave plasminogen generating angiostatin, whereas MMP-3 and MMP-9
generate a fragment from the basement membrane collagen type XVII, called endostatin. These fragments
inhibited endothelial cell proliferation and tumor growth (O’Reilly et al., 1994; 1997). Another fragment,
tumstatin is generated by MMP-9 through cleavage of the a3 chain of collagen IV (ColIVa3). This fragment
has been shown to be a ligand for avb3, an integrin highly expressed in blood vessels that are present in large
tumors. It has also been detected in the blood circulation, and recently, found to be acting as angiogenesis
inhibitor and tumor suppressor (Kalluri, 2003; Hamano et al., 2003). The authors detected lower levels of
this fragment in the circulation of MMP-9-deficient mice which led to increased growth of large tumors.
Shedding of SPARC (Secreted Protein Acidic and Rich in Cysteine), a protein that modulates cellular
interaction with the ECM, by MMP-3 produced peptides capable of regulating endothelial cell proliferation
and migration (Sage et al., 2003). We can conclude that MMP-9 has both pro- and anti-angiogenic
properties, as it is capable of not only promoting tumor growth, but also restraining the growth of tumors by
generating endogenous inhibitors of angiogenesis.
The av integrins play an important role in primary tumor growth in human melanoma (Felding-
Habermann et al., 1992). Endothelial cell integrins, including avb3, avb5, and a5b1 (Kim et al., 2000) have
also been essential for regulating angiogenesis. Although avb3 and avb5 inhibitors blocked tumor
angiogenesis in various models (Stupack and Cheresh, 2002), lack of these integrins did not block
developmental angiogenesis in b3 integrin knockout mice (Reynolds et al., 2002), suggesting that endothelial
cell integrins, as well as MMPs, can regulate tumor angiogenesis both positively and negatively.
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INTEGRINS AND GELATINASES IN INVASION AND METASTASIS
The initial step of tumor cell invasion is characterized by the breakdown of the basement membrane,
a process known to be dependent on type IV collagen-degrading enzymes, mainly MMP-2 and MMP-9.
Liotta obtained results where type IV gelatinase activity correlated with cancer metastasis (Liotta et al.,
1980). Endothelial cell proliferation and migration into the tumor tissue is mediated by angiogenic (ex.
MMP-9, VEGF, and bFGF) and lymphangiogenic factors that are released by tumor cells. During metastasis,
tumor cells must dissociate from the primary tumor, degrade the ECM and enter the blood or lymph
circulation by a process called intravasation. Tumor cells that have escaped from the immune system will
have to break through blood vessel and lymph vessel walls, this time by a process called extravasation, into
the surrounding tissue where they must be able to grow in a new environment (secondary tumor) (Mignatti
and Rifkin, 1993). Using DNA microarrays, primary tumor-gene expression profiles could be arranged in
classes of “good” and “poor” prognosis (Sorlie et al., 2001). Kang and colleagues performed DNA-
microarray analysis on human breast carcinoma cell lines that have metastasized to bone. These studies
revealed some of the genes (ex. MMP-1, MMP-2, CXCR4, IL-11, and CTGF) responsible for the increased
metastatic potential of breast cancer cells (Kang et al., 2003; Minn et al., 2005). Videomicroscopy studies
revealed that MMPs play a significant role in tumor metastasis, as TIMP-1 and MMP inhibitor batimastat
(BB-94) blocked the formation of tumors in secondary sites (reviewed in Chambers et al., 2002). The role of
MMPs in tumor invasion and metastasis has also been studied using antisense technology. For example,
antisense expression of MMP-9 resulted in decreased invasiveness of human glioblastoma cells (Kondraganti
et al., 2000). Also, injections of a replication-deficient adenovirus capable of expressing antisense uPAR and
MMP-9 transcripts led to the inhibition of invasion, tumor growth, and metastasis of non-small cell lung
cancer cells (NSCLC) (Rao et al., 2005). RNA interference-directed knockdown of uPA and its receptor
uPAR, and MMP-9 inhibited invasion and growth of prostate and glioma cells in vivo, respectively (Murali-
krishna et al., 2005; Lakka et al., 2005). MMP-2 induced expression also correlate with high metastatic
potential of prostate carcinomas (Stearns and Stearns, 1996). Furthermore, downregulation of the
endogenous MT1-MMP gene expression using RNA silencing technology also inhibited the invasion of
highly invasive fibrosarcoma HT1080 cells (Ueda et al., 2003). Gelatinases and MT-MMPs revealed a new
mechanism to control metastasis by cleavage of the metastasis suppressor gene, KiSS-1 (Takino et al., 2003).
Finally, recent studies supporting the in vitro data from double MMP-2:MMP-9-deficient mice demonstrated
that these enzymes cooperate in promoting the invasive phenotype of malignant keratinocytes in an
experimental model in vivo (Masson et al., 2005). Also, the number of metastatic colonies in MMP-9
deficient mice was significantly decreased in an experimental in vivo model where mice were injected
intravenously with melanoma or lung carcinoma cells (Itoh et al., 1999).
Changes in integrin expression and localization can also influence invasion and metastasis of tumor
cells (Maschler et al., 2005). Integrins were shown to be involved in the migration and liver metastasis of
large cell lymphoma cells and angiogenesis, as avb3 antagonists induced apoptosis and blocked cancer cell
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invasion (Brooks et al., 1994). a4b1 integrin has a dual role in cancer progression as it inhibited the initial
invasive growth while promoting metastatic spread of melanoma cells. A different study showed that
increased expression of this integrin could inhibit the invasive stage of metastasis formation (Qian et al.,
1994). Overexpression of a2b1 integrin had no effect on primary tumor growth but stimulated both
experimental and spontaneous metastasis (Chan et al., 1991). Blocking integrins with synthetic peptides
containing an RGD sequence, antibodies, or disintegrins (integrin-binding proteins isolated from snake
venom) has been demonstrated to intefere with tumor cell invasion and metastasis in vitro and in vivo
(Gehlsen et al., 1988; Curley et al., 1999). Importantly, cooperation between avb3 and MMP-9 increased
migration of metastatic breast cancer cells (Rolli et al., 2003). Increased expression of MMP-9 and aVb6
integrin promoted epithelial cell migration during tumor formation via a novel TNF-a-dependent mechanism
(Scott et al., 2004). Also, several reports show that uPA binding to its receptor, uPAR is a requirement for
tumor cell invasion and metastasis as this process is efficiently inhibited either by an amino-terminal
fragment of urokinase or a mutant plasminogen activator inhibitor-2 (PAI-2) (Wang et al., 2005).
Chemokines can also be involved in organ-specific metastatic growth of tumor cells. This hypothesis is
supported by a recent study which highlights the importance of chemokine receptors in breast cancer
metastasis in vitro and in vivo. For example, treatment of animals with a neutralizing anti-human CXCR4
monoclonal antibody inhibited cancer cell metastasis to lung tissue (Muller et al., 2001).
INTEGRINS AND GELATINASES IN CANCER-ASSOCIATED INFLAMMATION
Chronic inflammation is also associated with a variety of cancers, including breast, liver, prostate,
and skin (reviewed in Coussens and Werb, 2001). In human cancer, tumor cells are not the only source of
MMPs. MMPs, mainly gelatinases are predominantly produced by stromal cells, ranging from immune
(lymphocytes and dendritic cells), inflammatory (granulocytes and monocytes), and vascular cells (vascular-
and lymph-endothelial cells and pericytes). MMPs have been involved in the escape of cancer cells from
immune surveillance. The escape mechanism occurs through MMP-9-induced cleavage of the interleukin-2
receptor-a (IL-2Ra) (Sheu et al., 2001), TGF-b activation (Yu and Stamenkovic, 2000), and ICAM-1 and
ICAM-2 shedding (Mustjoki et al., 2001; Fiore et al., 2002; Sultan et al., 2004), thus suppressing T cell
proliferation and immune response against tumors.
Chemokines play an essential role in regulating directional migration of leukocytes. Proteolytic
cleavage of chemokines by MMPs can lead to enhanced or reduced leukocyte recruitment into tumors. For
example, MMP-9 activates the neutrophil chemoattractant IL-8 by cleavage, while it inactivates the CXCL7
precursor, the platelet factor-4 (PF-4), the growth-related oncogene-a (GRO-a), and stromal cell-derived
factor 1 (SDF-1) (reviewed in Egeblad and Werb, 2002). A cleaved form of MCP-3 produced by MMP-2 can
bind to CC-chemokine receptors, and unlike intact MCP-3, it abrogates chemotaxis and suppresses
inflammation (McQuibban et al., 2000). ET-1 processing by MMP-9 generates endothelin-1 (ET-1) that
induces secretion of MMP-9 from neutrophils (Fernandez-Patron, 2001), suggesting that MMPs are both
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effectors of leukocyte migration and regulators of the inflammatory response. The importance of chemokine
receptors in metastasis was demonstrated by inhibition of SDF-1-binding to its receptor. Dissociation of
SDF-1/CXCR-4 complex by blocking antibodies strongly reduced breast cancer metastasis to lungs and
lymph nodes in vivo (Müller et al., 2001). MMP-9 and VEGF are produced by mammary tumor-infiltrating
immune cells (Owen et al., 2003). Expression of MMP-9 by tumor-infiltrating macrophages promotes
angiogenesis as well as growth and invasion of xenografted ovarian cancer cells in vivo (Huang et al., 2002).
Several studies show that cancer cells can promote the secretion of MMPs by stromal cells in a paracrine
manner via secretion of growth factors, interleukins, and EMMPRIN (reviewed in Sternlinct and Werb,
2001). Various data have shown that recruitment of hematopoietic precursor cells is required for tumor
angiogenesis (Coussens et al., 2000). Indeed, transplantation of MMP-9-expressing bone marrow cells into
MMP-9-/- mice increased tumor growth, probably by delivery of MMP-9-producing monocytes into the
tumor vasculature.
ROLE OF INTEGRINS AND GELATINASES IN ACUTE LEUKEMIAS
Leukemia can be described as the uncontrolled proliferation of hematopoietic cells that lack the
ability to differentiate into mature blood cells. The precise role of gelatinase-expression in acute leukemias is
not clear. So far, it is known that invasiveness of many hematological malignancies, including myelo-
monocytic leukemias involves overexpression of proteolytic enzymes, such as the MMP-2 and MMP-9
(Janowska-Wieczorek et al., 1999; Kuittinen et al., 1999; Klein et al., 2001). MMP-9 is induced and secreted
in conditioned media of leukemic cell lines in response to extracellular stimuli, after pretreatment of cells
with chemokines, and after cell adhesion to the ECM (Xie et al., 1998; Wize et al., 1998; Klein et al., 2001;
Takafuji et al., 2003). Higher gelatinase-expression levels were detected in the bone marrow plasma of
patients with leukemia compared with normal controls. After chemotherapy, the levels of TIMP-1 and
TIMP-2 were significantly increased, whereas MMP-9 levels were lower in ALL and AML patients.
Accordingly, AML patients who achieved a complete remission showed significantly lower MMP-9 levels,
suggesting that MMP-9 could be a surrogate marker of leukemic status in these patients. Also, the low
MMP-9 expression levels in patients with leukemia correlated with increased survival (Lin et al., 2002).
Several reports have demonstrated the involvement of both MMP-2/-9 gelatinases and b2 integrins in
the growth and progression of myeloid and lymphoid neoplasms (Kossakowska et al., 1993; Noguchi et al.,
2001; Hayashibara et al., 2002). Selective MMP-9 expression is induced as a result of aMb2 integrin ligation
in PMNs (Wize et al., 1998) and aLb2 integrin ligation in T lymphoma cells (Aoudjit et al., 1998). Also,
studies from aM and aL integrin knockout mice confirm the importance of b2 integrins in mediating
leukocyte adhesion and migration (Bouvard et al., 2001). In accordance, high infiltration of leukemic blasts
in patients with AML strongly correlated with increased expression of both aLb2 and aMb2 integrins
(Noguchi et al., 2001). AML cell adhesion to bone marrow fibroblast monolayers seems to require both b1
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and b2 integrins, as antibodies against them inhibited the binding (Liesveld et al., 1993; Bendall et al., 1993;
Stucki et al., 2001). Interaction between leukemic cells and bone marrow stroma cells has been shown to
increase leukemic cell survival and chemotherapy-induced leukemia cell resistance (Garrido et al., 2001).
Increased vessel density was detected in the bone marrow of acute and chronic leukemia patients
compared with normal bone marrow, and known to be mediated by angiogenic factors such as VEGF and
basic fibroblast growth factor (bFGF) (Werb, 1997; Aguayo et al., 2000). Both increased plasma MMP-9 and
VEGF correlated with high leukemia cell infiltration, suggesting that MMP-9 and VEGF act co-operatively
in the process of leukemia cell invasion (Hayashibara et al., 2002). Another study showed that increased
vessel density was mediated by MMP-2 and MMP-9 overexpression in primary AML blasts by promoting
endothelial cell migration (de Bont et al., 2001). After achieving complete remission, the vessel number in
AML patients was restored to normal levels. Furthermore, a gene therapy approach using a retroviral vector
encoding for gelatinase inhibitors, endostatin and angiostatin strongly inhibited bone marrow angiogenesis
and leukemia tumor growth in vivo (Scappaticci et al., 2001). These data suggest that gelatinases could be
involved in leukemia progression. As a result, inhibitors of MMPs may be useful in treating hematological
malignancies.
THERAPEUTIC INTERVENTION WITH MMP AND INTEGRIN INHIBITORS
Due to the fact that integrins and MMPs are involved in tumor cell invasion and metastasis, a lot of
effort has been put over the past 20 years in designing integrin and MMP inhibitors (MMPIs). Although
endogenous inhibitors, such as TIMPs inhibited tumor growth in transgenic mouse models, their use in
cancer was limited due to poor pharmacokinetics, difficulties in protein administration, and broad spectrum
of inhibition. To date, several synthetic MMPIs have been developed, tested widely in clinical trials, and
classified into the following pharmacological groups: collagen peptidomimetics, non-peptidomimetics,
tetracycline derivatives, and biphosphonates (reviewed in Hidalgo and Eckhardt, 2001; Ala-Aho and Kähäri,
2005). The efficacy of these inhibitors in clinical trials is summarized in Table 6.
The design of collagen peptidomimetic MMP inhibitors is based on the collagen-peptide backbone
with zinc-binding hydroxamate moiety that coordinates the Zn2+ ion, thus inhibiting the MMP catalytic
activity. Batimastat was the first peptidomimetic inhibitor used in clinical trials for the treatment of
malignant tumors but is no longer used in clinical trials as it could not be administered orally. However,
treatment with marimastat, an oral MMPI variant of batimastat, significantly increased survival of patients
with gastric carcinoma (Bramhall et al., 2002). Treatment with marimastat was well tolerated by the patients,
except some small side effects translated with musculoskeletal pain, probably because of the need of MMPs
in normal remodelling of the connective tissue of tendons and joints. In patients with advanced pancreatic
cancer (a phase II study), marimastat showed comparable therapeutic effects as conventional therapy with
gemcitabine that was used (Bramhall et al., 2002). The survival of patients suffering from glioblastoma
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multiforme was also improved by using marimastat in combination with temozolomide, a cytotoxic drug
(Groves et al., 2002). Several non-peptidomimetic MMP inhibitors, including BMS-275291, AG3340, and
MMI270 have also been tested in clinical trials (Table 6).
Tetracyclines and biphosphonates have also been shown to block MMP activity (Boissier et al.,
2000; Cianfrocca et al., 2002). For example, a broad spectrum MMP inhibitor, metastat (or Col-3) showed
increased tumor cell toxicity, reduced tumor-induced angiogenesis, as well as antimetastatic activity (Seftor
et al., 1998; Lokeshwar et al., 2002), and is currently being tested in patients with Kaposi Sarcoma and brain
cancer in a phase II clinical trial. Periostat, a tetracycline used for the treatment of periodontal diseases, is the
only MMPI in the market.
Inhibitors Structure Specificity Status/Indication
MMP
Batimastat (BB-94)
Marimastat
(BB-2516)
BAY12-9566
AG3340
BMS-275291
MMI270
Metastat (Col-3)
Periostat
Neovastat (AE-941)
-
Integrin
Efalizumab/ Hu1124
Peptidomimetic
Peptidomimetic
Nonpeptidomimetic
Nonpeptidomimetic
Nonpeptidomimetic
Nonpeptidomimetic
Tetracycline derivative
Tetracycline derivative
Shark cartilage extract
Green tea extract
Humanised MAb
MMP-1, -2, -3, -7, -9
MMP-1, -2, -7, -9
MMP-2, -3, -9
MMP-2, -3
Broad spectrum
Broad spectrum
MMP-2, -9
Broad spectrum
Broad spectrum
MMP-2, -9
CD11a subunit
Development halted
Phase III/Gastric cancer
Phase II/Pancreatic cancer
Development halted
Phase II/III/No benefit
Phase I/II/NSCL
Phase I/Advanced cancer
Phase II/Kaposi sarcoma
Phase M/Periodontal disease
Phase II/Multiple myeloma
Phase III/NSCL
Phase III/Cancer
Phase III/Psoriasis
Anti-CD18
Anti-LFA1
Hu23F2G
Humanised MAb
Murine
Humanised MAb
CD18
CD18
CD11/CD18 integrin
PhaseII/ Myocardial infarction
Phase III/Allograft rejection
Phase II/Multiple sclerosis
Phase II/Myocardial infarction
Phase III/Stroke
LDP-01
LDP-02
Volociximab
& Erlotinnib
Humanised MAb
Humanised MAb
MAb
CD18 integrin subunit
a4b7 integrin
a5b1 integrin
Phase II/Allograft rejection
             /Stroke
Phase II/Ulcerative colitis
Phase II/metastatic NSCL
ATN-161
M200
Vitaxin / LM609
Antegren
PHSRN motif from FN
MAb
Humanised MAb
Humanised MAb
a5b1 integrin
a5b1 integrin
aVb3 integrin
a4b1 integrin
Phase I/NSCL
Phase II/Kidney cancer
Phase II/Sarcoma
Phase III/Multiple sclerosis
PhaseII/Colitis,Crohn’s disease
Tysabri/Natalizumab
Abciximab
Eptifibatide
Tirofiban
Cilengitide
Altocor/ Lovastatin
MAb
Chimeric Ab
Cyclic heptapeptide
Peptidomimetic
Cyclic RGD peptide
Chemical
a4b1 integrin
aIIbb3, aVb3, aMb2
aIIbb3 integrin
aIIbb3 integrin
aVb3/aVb5 integrins
aLb2 integrin
Phase M/Multiple sclerosis
FDA approved
FDA approved
     ”    ”  /Myocardial infarction
Phase II/GBM
FDA approval/atherosclerosis
Table 6. MMP and integrin antagonists in clinical trials. NSCL, non-small-cell lung cancer; FN, fibronectin; Phase
M, on the market; ; GBM, glioblastoma multiforme; Mab, monoclonal antibody; FDA, food and drug administration.
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Interestingly, compounds (TSRI265) capable of inhibiting interactions between MMPs and integrins showed
promising results in animal experiments (Silletti et al., 2001). Also, a cyclic peptide, CTTHWGFTLC
discovered by phage display technology as a selective gelatinase inhibitor could block cell migration and
tumor growth in a gelatinase-dependent manner (Koivunen et al., 1999).
The failure of MMPIs in several cancer clinical trials is not surprising (reviewed in Coussens et al.,
2002). Most MMPIs were used to treat patients in late-stage tumors, whereas most results obtained from
animal experiments show the need for targeting MMPs in early stages of cancer progression. Also, these
inhibitors target all MMPs, many of which are needed for the processing of anti-angiogenic factors,
including angiostatin and endostatin. For that, increasing the selectivity of these compounds (for example,
for gelatinases involved in metastasis) could solve the problem of side effects reported so far. MMPIs are
known to target also ADAMTS, enzymes capable of reducing tumor growth by blocking tumor angiogenesis
(Vazquez et al., 1999). It should be taken in consideration that other proteases are upregulated during tumor
progression that could compensate the loss of MMPs. These proteases should be identified and targeted
along with MMPs.
The involvement of integrins in tumor cell invasion and metastasis became clear after using aV
(Eliceiri and Cheresh, 1999) or b1 (Senger et al., 2002) subunit-blocking antibodies or small synthetic
antagonists generated from the ligand’s-recognition sequence. Humanized mAbs, Vitaxin and Efalizumab
against aVb3 (Posey et al., 2001) and aL subunit of aLb2 (Lebwohl et al., 2003) respectively, and the
synthetic, cyclic Arg-Gly-Asp (RGD) peptide motif (Dechantsreiter et al., 1999) present in many integrin
ligands were the three among many other integrin-binding agents that have entered cancer clinical trials (see
Table 6). Efalizumab and a recombinant mAb against a4b1, natalizumab have shown a great promise in the
treatment of psoriasis (Lebwohl et al., 2003), as well as in multiple sclerosis and Crohn’s disease,
respectively (Miller et al., 2003; Ghosh et al., 2003). However, b3 and b5-integrin knockout mice showed
increased expression of VEGFR-2 receptor, leading to enhanced tumor angiogenesis (Reynolds et al., 2002).
Taken together, MMP and integrin knockout models and inhibitors can increase our understanding of the
multiple functions of these molecules in several diseases, including cancer. Such studies may be used to
develop therapeutic agents which can interfere with the integrin and MMP function on invasive tumor cells
and blood vessels.
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AIMS OF THE PRESENT STUDY
The aims of the present study were:
1. To study whether b2 integrins could act as receptors for MMP-2 and MMP-9 on the surface of leukocytes
and leukemic cell lines, and by which binding mechanism.
2. To identify peptides by phage display technology capable of inhibiting the interaction between leukocyte
integrins and MMPs.
3. To study the role of the integrin/proMMP complexes in leukocyte migration in vitro and in vivo.
4. To identify small-molecule compounds that bind to integrins, which could be more suitable for drug
development.
5. To determine the role of the aMb2 integrin/MMP-9 complex as a functional target for inhibition of
leukemia cell dissemination and growth in vivo.
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MATERIALS AND METHODS
Detailed descriptions of the materials and methods are found in the original publications.
Materials and Methods Original Publications
Antibodies, synthetic peptides, cell lines I-IV
Peptide biosynthesis and chemical synthesis I
Cell culture and neutrophil isolation I-IV
Purification of leukocyte integrins I, II
Expression and purification of integrin I domains
and MMP-9 recombinant proteins
I-IV
Enzyme-linked immunosorbent assay (ELISA) I, II
SDS-PAGE and immunoblotting I-IV
Coprecipitation experiments I
Immunoprecipitation I
Cell adhesion and Transwell migration I-IV
Transendothelial migration/Chemotaxis assay II
Immunohistochemical staining of tissues IV
Gelatin zymography I, II
Confocal microscopy I, II, IV
Phage display pannings I
Phage binding assays I
Subcellular fractionation II
Cell surface labeling using 125Iodine and periodate-
tritiated sodium borohydride
II, IV
Cell surface biotinylation IV
MMP-9 cell surface release I
Binding of MMPs to purified integrins I
Pepspot I
Metabolic radiolabeling II
Antibody production and purification IV
Cell viability and proliferation assay III, IV
Peptide affinity chromatography IV
Cell binding assay using 125I-MMP-9 domains IV
RNA interference and RNAi-transfections IV
Thioglycolate-induced peritonitis in vivo II
Leukemia cell dissemination in vivo IV
Human leukemia xenograft models in vivo IV
Pericellular proteolysis IV
Small molecule compound library screening III
Statistical analysis II, IV
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RESULTS
Identification of DDGW, an aMb2 integrin-binding peptide that inhibits leukocyte migration in vitro
(I).
Using phage peptide display libraries, we selected peptides that interact with the aM I domain. The
consensus D/E-/D/E-G/L-W determined by this approach was clearly different from other b2 integrin-binding
peptides reported so far. We chose the peptide CILWMDDGWC (DDGW) for further experiments as this
peptide-bearing phage showed strong binding to the aL/M ? I domains and this was readily inhibited by low
concentrations of the DDGW peptide. Data from protein databases revealed that this motif is present and is
highly conserved in the catalytic domain of MMPs, including gelatinases MMP-2/-9 (Figure 1A). To find a
dominant integrin-binding site in the catalytic domain of proMMP-9 was unexpected, as previous reports
suggested another MMP domain to be required for integrin binding. For example, the hemopexin domains of
MMP-2 and MMP-1 mediated binding to aVb3 (Brooks et al., 1996; Brooks et al., 1998) and a2b1 integrins
(Dumin et al., 2001; Stricker et al., 2001).
No MMP has been ever reported to bind to the leukocyte b2 integrins. We therefore set out to study
whether MMP-9 in particular could be a ligand of the b2 integrins as MMP-9 gelatinase is the major
leukocyte MMP and is induced during b2 integrin activation. Binding assays with the aM I domain revealed a
single active peptide that located to the MMP-9 catalytic domain. The sequence of the I domain-binding
peptide was QGDAHFDDDELWSLGKGVVV and it contained a similar binding motif to the one identified
by phage display. The active MMP-9 peptide contained four consecutive amino acids with negative charges,
DDDE. Alanine scanning mutagenesis on both DDDE- and DDGW-containing peptides significantly
abrogated I domain binding Figure 1E). Also, peptides derived from other known integrin ligands, including
myeloperoxidase, catalase, thrombospondin-1 and complement protein iC3b strongly bound the I domain in
this assay and the double alanine mutations caused a loss of binding (Table I).
Progelatinases bound in a concentration-dependent manner to coated aMb2 integrin. The binding of
gelatinases was observed with both aMb2 and aLb2 integrins and their corresponding I domains. ProMMP-9
bound like a true integrin ligand, as the cation chelator EDTA nearly completely prevented the binding. The
DDGW peptide was an efficient inhibitor and it inhibited proMMP-9 binding to the aM I domain with an
IC50 of 20 µM. Curiously, MMP-2 and MMP-9 lost the integrin binding ability after activation by trypsin or
APMA (Figure 2). Furthermore, proMMP-9 and aMb2 were found to co-localize on the cell surface of
activated leukemia cells. Cell surface labeling and coimmunoprecipitation studies further demonstrated the
occurrence of the complex in leukemic cell lines (Figure 7). We suggest that the MMP-9 co-localizing with
aMb2 is the proMMP-9, as the activated MMP-9 did not bind to aMb2.
We then studied the effect of the DDGW peptide on adhesion and migration of human
myelomonocytic THP-1 cells. Phorbol-ester activated cells efficiently bound to the DDGW peptide, whereas
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there was no binding in the absence of cell activation. The acute myeloid leukemic cell line OCI/AML-3 also
avidly adhered to DDGW, whereas human fibrosarcoma HT1080 cells which lack b2 integrins did not.
DDGW did not block cell adhesion to fibrinogen and ICAM-1. Both the DDGW and CTT peptides inhibited
the migration of THP-1 cells on the LLG-C4-GST substratum. Unlike DDGW, CTT was also capable of
inhibiting the migration of b2 integrin lacking cells, HT1080 (Figure 9). These results suggest an important
function for the integrin-progelatinase complex in leukocyte migration.
Blocking the progelatinase/b2 integrin complex inhibits migration of PMNs to an inflammatory site in
vivo (II)
Previously, endogenous neutrophil elastase, proteinase 3, and cathepsin G have all been reported to
bind to aMb2 in PMNs (Cai and Wright, 1996). Immunofluorescence and surface labeling with THP-1
leukemic cells from earlier experiments showed an intense intracellular colocalization of aMb2 integrin and
proMMP-9 (I; Figure 7B). Staining of resting and activated PMNs with integrin and MMP antibodies
showed even more intense intracellular colocalization. After PMA-treatment to cause exocytosis of
intracellular granules, the intracellular staining decreased and aMb2 integrin and MMP-9 colocalized to the
cell surface. Although proMMP-9 is known to localize to the same intracellular granules as the aMb2
integrin, association of proMMP-9 with aM?2 intracellularly has not been shown before.
Immonoprecipitation studies with integrin and MMP antibodies were performed on purified
azurophilic-, specific-, gelatinase-, secretory vesicle- and plasma membrane-fractions from PMNs. In non-
activated PMNs, the proMMP-9/aMb2 complex was immunoprecipitated from the gelatinase granules,
whereas after PMA-stimulation, it was translocated to the PMN cell surface. The biosynthesis of the
endogenous complex was also investigated in the THP-1 leukemic cell line, which is amenable for such
studies. The complex was detected at 2 h and 4 h time points by immunoprecipitation from [35S]-methionine
pulsed cells. These results indicate that the proMMP-9 association is an early event for the integrins and that
the immunoprecipitated material does not represent endocytosed or recycling integrins. This is a more
plausible mechanism for the MMP/integrin complex formation than binding of a secreted MMP to the
integrin on the cell surface. First of all, the integrin could transport the endogenously-bound proMMP-9 to an
appropriate site without competition by extracellular MMP inhibitors and integrin ligands. Secondly, as the I
domain of aMb2 does not bind active MMP-9 (I, Figure 2A), the integrin could regulate the timing of
proMMP-9 activation and release of the active enzyme.
Experiments with recombinant MMP-9 domains gave further support for our finding that a site
interacting with the integrin is present on the MMP-9 catalytic domain (II, Figure 4B) and we developed an
active I domain binding peptide that was only six residues in length. This peptide, HFDDDE, corresponds to
a linear sequence from the MMP-9 catalytic domain and efficiently competed with proMMP-9 binding to
aMb2 (IC50 of 20 µM) or its purified I domain. ICAM-1 and fibrinogen did not compete with either proMMP,
implying different binding sites for the matrix proteins and proMMPs in the I domain.
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Then, we investigated the effect of the HFDDDE peptide on the adhesion and migration of PMNs.
After integrin activation, PMNs exhibited an ability to adhere on proMMP-9. Cell adherence was inhibited
by HFDDDE (50µM), DDGW (50µM), the soluble aM I domain and the MEM170 antibody, indicating b2
integrin-directed binding. Similar results were obtained using the aM?2 L-cell transfectants. The in vitro
migration of PMNs was studied either with transwell or transendothelial layer assays. Chemotaxis with C5a
or TNF-a increased PMN transmigration by 5-10 fold and inhibition was obtained either by DDGW,
HFDDDE, CTT or aM and MMP-9 antibodies (II, Figure 6).
To study neutrophil migration in vivo, we used a mouse model of thioglycolate-induced peritonitis.
Approximately 20-fold more PMNs were present intraperitoneally after thioglycolate-stimulus in comparison
to the PBS control. The effects of DDGW and HFDDDE peptides were concentration-dependent and up to
80 % inhibition was obtained by doses of 0.1mg/kg and 4 mg/kg per mouse, respectively. Inflammatory
PMNs from the pritoneal cavity were stained positively for the proMMP-9/aMb2 complex, whereas cells
collected after PBS injection lacked the complex; they expressed the integrin but had no cell-surface MMP-
9. DDGW and HFDDDE prevented the increase in gelatinase levels present in the peritoneal cavities in
accordance with the inhibition of cell migration (II, Figure 7). Taken together, these results suggest that the
proMMP-9/aMb2 complex may play a role in PMN motility in vitro and in vivo.
Identification of an aMb2 integrin–small binding molecule which inhibits integrin-dependent leukemia
cell migration (III)
We developed an assay for the identification of small-molecules that interact and compete with a
DDGW peptide-bearing phage for binding to the aM I domain of aMb2 integrin. By this technique, we were
about to select compounds that bind to the target protein with a high affinity, are more stable against
proteolysis and less susceptible to rapid clearance in vivo. The most active compound, IMB-10 bound six
times stronger to both aL and aM I domains than the peptide and inhibited DDGW phage binding.
Surprisingly, unlike DDGW, IMB-10 failed to disrupt the interaction between the I domains and proMMP-9.
However, IMB-10 was capable of stabilizing the active conformation of the I domain as it increased the
binding to integrin ligands (Figure 2). In addition, aMb2 integrin-expressing cells adhered strongly to coated
integrin ligands in the presence of IMB-10 and failed to detach in the presence of cation-chelating agents,
such as EDTA (Figure 4). Furthermore, single amino acid point mutations in the integrin aM I domain
indicated that Lys245 would be an important residue in mediating binding to progelatinases. Also, mutations
in the hydrophobic pocket accommodating the C-terminal ?-helix, which is known to regulate integrin’s high
affinity state conformation, inhibited the I domain’s ability to be induced by IMB-10.
Finally, IMB-10 showed no signs of toxicity at concentrations of 25 µM and efficiently inhibited
integrin-dependent migration when added to THP-1 and OCI-AML-3 cells in vitro (Figure 5). This
compound had no effect in mobilization of cells that lack leukocyte b2 integrins. Similarly, the function of
IMB-10 was also tested in a thioglycolate-induced peritonitis model in vivo (Figure 6). The number of
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leukocytes that were recruited to the peritoneum was reduced by 70 % at three hours post-induction of the
inflammation.
Inhibition of human leukemia tumor xenografts by blocking the interaction between integrins and
progelatinases (IV)
We recently demonstrated that proMMP-9 bound via its catalytic domain to aM and aL I domains of
b2 integrins on the surface of leukemic cell lines (I, Figure 2B). This binding was inhibited by the MMP-9-
related peptide, HFDDDE derived from the MMP catalytic domain sequence, and by the b2 integrin ligand,
DDGW obtained by phage display (II, Figure 4C). Next, we determined the affinity of proMMP-9 to the cell
surface using recombinant catalytic and C-terminal hemopexin domains. 125I-?proMMP-9 bound to OCI-
AML-3 cells with high affinity [dissociation constant (Kd) = 93 nM ± 18 nM; n=3]. Inhibition experiments
with the aM and aL antibodies, and integrin-binding peptides indicated that aMb2 and aLb2 integrins serve as
receptors for ?proMMP-9. We also used short interfering RNAs (siRNA) to suppress the endogenous aM
integrin gene on OCI-AML-3 and THP-1 cells. 125I-?proMMP-9 binding to the RNAi-treated cells was
significantly reduced as compared to untreated cells. One of the aM siRNAs suppressed integrin expression
as shown by protein levels at 72 h post-transfection and by FACS. aM siRNAs did not affect proMMP-9
protein expression levels. RNAi-treated cells showed weakened binding to ICAM-1- or proMMP-9-coated
surfaces indicating the loss of integrin function. Taken together, these data indicate that b2 integrins, possibly
both aMb2 and aLb2, anchor the proMMP-9 catalytic domain to the cell surface (IV, Figure 3).
As the peptides efficiently inhibited leukemia cell migration in several in vitro assays (I, Figure 9B;
II, Figure 6B), we set out to study the role of MMP-integrin complexes in leukemia cell growth and
dissemination in mouse models. Exposure of human OCI-AML-3 and THP-1 leukemic cells in vitro to either
HFDDDE or DDGW peptides at concentrations as high as 500 µM showed no signs of cytotoxicity.
However, when administered to mice, the peptides significantly suppressed the growth of OCI-AML-3 and
THP-1 xenografts, the linear HFDDDE hexapeptide being consistently more active than the cyclic 18-mer
DDGW. Nude mice were injected subcutaneously with human OCI-AML-3 cells and divided into 5 groups
(n = 8 mice/group). Peptides were administered i.v. at day 4 postinoculation and at concentrations of 10
mg/kg 5 times a week. The HFDDDE- and DDGW-treated mice had significantly smaller tumors at day 20
compared to sequence related but inactive control peptide groups. The tumor suppressive effect of HFDDDE
lasted longer than that of DDGW and at day 160, when the experiment was ended, 3 out of 8 tumor-bearing
mice in the HFDDDE group showed tumor regression. Treatment with HFDDDE and DDGW peptides led to
a statistically significant increase in survival that was extended by 140 days and by 50 days, respectively.
Similar results were obtained with the peptides, this time by treating THP-1 tumor-bearing mice (IV, Figure
1).
Several reports demonstrate that tumor-infiltrating leukocytes and increased tumor angiogenesis
contribute to the survival, growth, and progression of various malignant tumors (Folkman et al., 1995; Lin
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and Pollard, 2004). We therefore checked whether the integrin-binding peptides had any effect on host’s
immune system and tumor vascularization. Histological examination of tumor sections with an antibody
against mouse aMb2 integrin showed diminished host infiltrating leukocytes and blockage of blood vessel
formation in HFDDDE- and DDGW-treated tumors compare to saline-treated. As the subcutaneously
growing leukemias may not properly mimick human leukemias which disseminate via the blood, we next
examined leukemia dissemination in mice at approximately 40 days i.v. postinoculation of OCI-AML-3
cells. Mice subjected to HFDDDE-peptide treatment showed decreased tumor burden and lower number of
visible tumor nodules in the liver, lungs, and gastrointestinal system (IV, Figure 1). In a different mouse
model, the HFDDDE peptide and an antibody raised against it inhibited the infiltration of 125I -labeled OCI-
AML-3 cells to the liver, bone marrow, and spleen. The HFDDDE peptide also inhibited proMMP-9 binding
to the surface of AML cells, blocked cell-mediated gelatin degradation, and “stabilized” several cell surface
proteins, including b2 integrins. In addition, the MMP-9 levels were significantly increased in the serum of
mice which have been treated with the integrin-binding peptides, HFDDDE and DDGW (IV, Figure 2).
These results indicate that disruption of the integrin/MMP complexes presented here provides an
experimental framework to yield AML-targeted therapies..
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DISCUSSION
Extensive effort has been made in developing small molecules, peptides and peptidomimetics
capable of inhibiting interactions which occur on the cell surface. Several linear and cyclic peptides derived
from sequences of b2 integrins, ICAMs, and ECM proteins have been shown to have inhibitory effects in
vitro and in vivo. Indeed, ICAM-1-derived peptides can control immune responses in autoimmune diseases
and allograft rejection by simply blocking ICAM-1-binding to aLb2 integrin. Peptides derived from the
sequence of b1- and b2-integrins have been also shown to be potent anti-inflammatory agents by blocking
integrin-mediated adhesion of leukocytes (Yusuf-Makagiansar et al., 2002). Furthermore, inhibition of an
integrin-MMP cell-surface complex, aVb3/MMP-2 dramatically suppressed angiogenesis in vivo, suggesting
that this interaction is essential for endothelial cell proliferation and migration (Silletti et al., 2001). Such
reagents were reported not only to interfere with ligand binding, but also could stabilize integrin
conformations. Conformational changes after ligand or peptide binding is known to induce exposure of
neoepitopes referred to as ligand-induced binding site epitopes (LIBS) (Takagi et al., 1997; Lu et al., 2001b).
Finally, integrin-directed small molecules have entered phase I and II clinical cancer trials as they showed
strong inhibition of tumor angiogenesis (Kerbel et al., 2000). Also, peptides containing the RGD sequence
have been demonstrated to inhibit experimental tumor metastasis in animal models (Curley et al., 1999).
In our study, a cyclic peptide DDGW discovered by phage display, both inhibited proMMP-9/aMb2
complex formation and leukocyte migration in vitro and in vivo. However, this motif did not block leukocyte
adhesion to ICAM-1 and fibrinogen, suggesting the integrin-bound MMP is essential for degradation of
integrin-directed bonds to matrix proteins. We also discovered a small molecule recognizing the aMb2
integrin which had no effect on the integrin/MMP complex formation but instead it enhanced the binding of
the integrin I domain to its ligands by stabilizing the active conformation of the I domain.
Studies on the role of MMP-9 in leukocyte migration have been controversial. For example, some
reports have supported MMP-9 function in leukocyte migration (Keck et al., 2002; Lee et al., 2003), whereas
others have not (Betsuyaku et al., 1999; Allport et al., 1999). These findings are not surprising as MMPs are
known to have overlapping functions and other MMPs within the family could compensate for the loss of
MMP-9.
The molecular basis of the integrin-MMP interaction was first studied in vitro using purified
integrins or integrin domains and purified MMPs, both in ELISA and immunoprecipitation
experiments. Cell surface labeling and coimmunoprecipitation studies further demonstrated the
occurrence of the complex in leukemic cell lines. Experiments with recombinant MMP-9 domains
gave further support for our finding that the site interacting with the integrin is present on the
MMP-9 catalytic domain (Figure 6; left panel). The putative binding site was revealed by using
synthetic peptides as 20-mers, spanning the entire MMP-9 sequence.
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Figure 6. Structure of the C-terminally truncated proMMP-9. The pro-domain and catalytic domain, as well as the three
fibronectin type II (FnII) repeats are shown in green, cyan/blue, and  light pink, light magenta, and magenta,
respectively. The HFDDDE peptide motif, located in the catalytic domain is shown in a higher magnification (right
panel) and amino acids are drawn as ball-and-stick models. The blue b strands and cyan a helices belong to the
catalytic domain of pro-MMP-9. Calcium atoms are depicted in yellow and zinc atoms in orange. The proMMP-9
pictures were generated using Molscript and Raster3D programs. Gimp-2.2 (http://www.gimp.org) has been used to
modify the pictures from the PDB entry 1L6J (Elkins et al., 2002). The figure is printed with the permission of Minna
Varis.
The binding motif in these peptides was homologous to our phage display integrin-binding peptide and to a
sequence element, HFDDDE found in the catalytic domain of MMP-2 and -9 (Figure 6; right panel). This
motif could also be involved in chelating the two Ca2+ ions which are coordinated by the negatively charged
amino acids, D205 and E208. Although the approach to mimick features of complex protein structure with
small peptides may appear somewhat simplified, our study came up with peptides capable of blocking the
interaction between MMP-9 and aMb2 integrin. However, we can exclude the possibility that these peptides
also affect other b2 integrin ligands than proMMP-9.
A very interesting finding was the observation that the proenzyme, but not the activated MMP bound
to the integrin. Although mechanistically unclear (the site identified to mediate the binding in MMP-9 is not
within the prodomain), this feature could be important for the control of MMPs activity in vivo. Also, the
location of the binding site being close to the MMP catalytic center further suggests a mechanism for
evading inhibition by TIMPs or a2-macroglobulin. In the absence of inhibitors, the cell surface-localized
proMMP-9 would be readily susceptible for activation and substrate hydrolysis, which can occur in the
presence of the intact propeptide (Bannikov et al., 2002). In addition, our results suggest that proMMP-9
binds preferentially to the extended conformation of the integrin as the integrin-binding compound, known to
stabilize the active conformation of the aM I domain strongly increased its binding to proMMP-9. It remains
to be seen whether other integrins conformations, such as the bent (inactive) and intermediate forms (Xiong
et al., 2001; Takagi et al., 2002) can support proMMP-9 binding.
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Moreover, we present evidence that proMMP-9/aMb2 complex is stored within the intracellular
granules in resting PMNs and translocated to the cell surface upon cell stimulation (Figure 7). This is a more
plausible mechanism for the MMP/integrin complex formation than binding of a secreted MMP to an
unoccupied integrin on the cell surface. Also, leukocyte integrins could play a role in targeting of proMMPs
to a site where proteolytic activity is needed. However, it remains to be determined by which mechanism
(pro)MMP-9 is located at the surface of cells lacking b2 integrins.
Activation of cells with cytokines, chemokines, and chemical agents is known to induce the release
of transmembrane proteins, including TGF-a, TNF-a, and L-selectin (Arribas et al., 1996; Fiore et al.,
2002), a process that is known to be essential for regulating the cellular functions of these receptors. It has
been shown that proteolytic processing of fibrinogen regulates aMb2 integrin-mediated leukocyte adhesion
and detachment on this substrate (Lishko et al., 2002). The aMb2 integrin ligands ICAM-1 and fibrinogen,
which are important for leukocyte migration act also as substrates for MMP-9 (Lelongt et al., 2001; Fiore et
al., 2002; Sultan et al., 2004). Accordingly, collagenolysis by MMP-1 is known to be required for efficient
migration of keratinocytes on type I collagen matrix (Pilcher et al., 1997). Finally, MT1-MMP-mediated
shedding of laminin-5 leads to stimulated epithelial cell migration (Koshikawa et al., 2000).
Figure 7. Schematic summary of the integrin/MMP complex in PMNs. The ?M?2/MMP-9 complex is formed in
PMN intracellular granules and can be rapidly mobilized to the cell surface after exposure to degranulation stimuli, such
as TNF-b, LPS, and fMLP. PMN degranulation can also be achieved when cells are in contact with ECM proteins.
Upon PMN activation, cell-surface receptors are routinely shed from PMNs. Loss of these receptors is mainly due to
PMN-derived MMP activity, a process that facilitates PMN rolling and migration via degradation of the vascular
basement membrane during PMN extravasation.
The physiological role of MMP-2 and -9 is not fully understood, but to our current knowledge they
are involved in the processing of the extracellular matrix during growth and tissue differentiation, probably
as critical factors for cell motility. Proteases and integrins for such a function have been expected to be
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colocalized at the surface of migrating cells. Most MMPs, however, are secreted enzymes and the search for
cell surface receptors for MMPs has been going on for years. At the moment there are some hundred
publications describing receptors, such as integrins for various MMPs, among them MMP-2 and -9.
Likewise, gelatinase activity has been found in the membrane of leukocytes, but the identification of the
leukocyte integrins as gelatinase receptors is new to our knowledge and likely to extend our understanding of
further mechanisms involved in leukocyte migration. Studies from knockout models for integrins, including
leukocyte b2 integrins confirm their involvement in various steps of cancer development. Eventually, tumor
growth and metastasis could be blocked by interfering with integrin function on tumor cells and blood
vessels. This study provides evidence that a small, negatively charged peptide, derived from the catalytic
domain of MMP-9, efficiently blocks aMb2/MMP-9 complex formation, leukemia cell-mediated pericellular
proteolysis, leukemia cell extravasation and growth in vivo. Several MMP inhibitors have been developed
and tested in clinical trials but the results have been disappointing. Based on our findings, new and more
effective cancer therapeutics could be achieved by blocking, not only MMPs alone but their association with
integrins or other cell surface receptors. Selective antagonists of the MMP-9/aMb2 integrin interaction may
not only be therapeutic in leukemias but also in other types of malignancies where tumor-infiltrating
leukocytes enhance tumor growth.
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